Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. by unknown
Accountability for the global health 
sector strategies 2016–2021: actions 
for impact
Global progress report 
on HIV, viral hepatitis 
and sexually transmitted 
infections, 2021

Global progress report 
on HIV, viral hepatitis 
and sexually transmitted 
infections, 2021
Accountability for the global health 
sector strategies 2016–2021: actions 
for impact
Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 
Accountability for the global health sector strategies 2016–2021: actions for impact
ISBN 978-92-4-002707-7 (electronic version)  
ISBN 978-92-4-002708-4 (print version)
© World Health Organization 2021
Some rights reserved. This work is available under the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.
org/licenses/by-nc-sa/3.0/igo). 
Under the terms of this licence, you may copy, redistribute and adapt the work for non-
commercial purposes, provided the work is appropriately cited, as indicated below. In any use 
of this work, there should be no suggestion that WHO endorses any specific organization, 
products or services. The use of the WHO logo is not permitted. If you adapt the work, then 
you must license your work under the same or equivalent Creative Commons licence. If you 
create a translation of this work, you should add the following disclaimer along with the 
suggested citation: “This translation was not created by the World Health Organization (WHO). 
WHO is not responsible for the content or accuracy of this translation. The original English 
edition shall be the binding and authentic edition”. 
Any mediation relating to disputes arising under the licence shall be conducted in accordance 
with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/
amc/en/mediation/rules/).
Suggested citation. Global progress report on HIV, viral hepatitis and sexually transmitted 
infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for 
impact. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/
bookorders. To submit requests for commercial use and queries on rights and licensing, see 
http://www.who.int/about/licensing. 
Third-party materials. If you wish to reuse material from this work that is attributed to a 
third party, such as tables, figures or images, it is your responsibility to determine whether 
permission is needed for that reuse and to obtain permission from the copyright holder. The 
risk of claims resulting from infringement of any third-party-owned component in the work 
rests solely with the user.
General disclaimers. The designations employed and the presentation of the material in 
this publication do not imply the expression of any opinion whatsoever on the part of WHO 
concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps 
represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that 
they are endorsed or recommended by WHO in preference to others of a similar nature that 
are not mentioned. Errors and omissions excepted, the names of proprietary products are 
distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this 
publication. However, the published material is being distributed without warranty of any kind, 
either expressed or implied. The responsibility for the interpretation and use of the material 
lies with the reader. In no event shall WHO be liable for damages arising from its use. 
Layout by 400 Communications.





1. A backdrop of crisis, resilience and innovation 1
1.1 Major epidemics with lessons across diseases 8
1.2 Disruption and opportunities arising from COVID-19 18
2. Progress towards impact 28
3. Progress by strategic direction 34
3.1 Information for focused actions  36
3.2 Interventions for impact  40
3.3 Delivering for equity  46
3.4 Financing for sustainability  52
3.5 Innovation for acceleration  58
3.6 Cross-cutting actions 64
3.7 WHO actions 68
4. Progress by WHO region 70
4.1 African Region 70
4.2 Region of the Americas 73
4.3 South-East Asia Region 76
4.4 European Region 79
4.5 Eastern Mediterranean Region 82
4.6 Western Pacific Region 85
5. Looking ahead to 2030 88
References 90
Progress on the reduction and elimination of 
HIV, viral hepatitis and sexually transmitted 
infections looks very different now than it 
did a year ago. Across the world, the COVID-19 
pandemic has disrupted essential health services, 
including those needed to support the prevention, 
diagnoses, and treatment of these diseases. 
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Foreword v
The 2021 global progress report on HIV, viral hepatitis 
and sexually transmitted infections, is an opportunity to 
take stock of the progress achieved in addressing these 
diseases to date, the setbacks caused by the pandemic, 
and the lessons learned for the coming decade.
This report documents the implementation of the 
2016–2021 global health sector strategies for HIV, viral 
hepatitis and sexually transmitted infections. Drawing 
on data from multiple sources, it analyses progress and 
highlights the continuing gaps. It reviews the activities 
undertaken over the last five years against WHO’s five 
strategic directions: information, services and essential 
interventions, equity, financing and innovation.
There has been impressive progress in many areas 
of the response, including the large-scale expansion 
of HIV treatment, innovations in a cure for hepatitis 
C virus, and increasing coverage of immunization for 
hepatitis B virus and for human papillomavirus – the 
latter a critical intervention to prevent cervical cancer. 
Nevertheless, we are not on track to eliminate these 
preventable and treatable diseases, which together 
result in more than one million new infections every 
day, and more than two million deaths and 1.2 million 
new cases of cancer every year. In too many countries, 
priority interventions remain inaccessible to the 
populations most severely affected and at higher risk.
The COVID-19 pandemic has impeded the delivery 
of core services that tackle HIV, viral hepatitis, and 
sexually transmitted infections. During this incredibly 
challenging year, we have witnessed the ability of 
health and community systems to adapt to continue 
to reach people in need. The lessons learned from the 
innovations developed during the pandemic response 
can inform core service delivery programming, as part  
of the overall effort to achieve universal health coverage. 
The report highlights the importance of people-
centred services and the urgent need to focus on 
inequalities and populations left behind: adolescent 
girls and young women, their male partners, gay men 
and other men who have sex with men, transgender 
people, people who inject drugs, sex workers, people 
in prisons and all vulnerable populations. 
Our goal for the coming decade is to get back on track 
by increasing the equitable delivery of services for 
HIV, viral hepatitis and sexually transmitted infections 
across the world. This report lays the groundwork for 
the next phase of that work. 
The collaboration of and contributions from 
health ministries were invaluable in preparing 
this report. The contribution of technical 
partners was also crucial, especially the CDA 
Foundation, which supported each stage together 
with Imperial College, the University of Bristol, 
the International Agency for Research on 
Cancer and UNAIDS. The United States Centers 
for Disease Control and Prevention, the United 
States Agency for International Development, 
the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR), the Global Fund to 
Fight AIDS, Tuberculosis and Malaria, the Bill 
& Melinda Gates Foundation and UNITAID are 
major sources of financial support for WHO’s 
work illustrated here and enabled WHO to 
produce this report.
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1. HIV, viral hepatitis and sexually transmitted 
infections (STIs) are major public health 
threats worldwide. They account for more 
than 2.3 million people dying per year, 
which represents 14% of all deaths from 
infectious and parasitic diseases, digestive 
diseases and cancer. They also result in 
more than 1 million people newly infected 
each day and 1.2 million people developing 
cancer each year. If we lose focus now, the 
progress achieved so far will plateau with 
the risk of resurgence. Time is running 
short. To reach the 2030 targets, we need to 
accelerate progress, address specific gaps 
in implementation, and bring innovation to 
scale across the three diseases.
2. The epidemics and responses are 
at different stages. This strategy 
implementation period has seen tremendous 
progress, including achievement of the 
Sustainable Development Goals target to 
reduce the incidence of hepatitis B virus.
• The global target of the Sustainable 
Development Goals and the global health 
sector strategy to reduce the incidence 
of hepatitis B has been met, as measured 
by the prevalence of hepatitis B surface 
antigen to less than 1% by 2020 among 
children younger than five years. Supported 
by childhood immunization and prevention, 
the reduction in the incidence of hepatitis 
B infection is one of the few Sustainable 
Development Goals health targets that is 
on track to be achieved. Sustained and 
regionally focused scale-up of the birth dose 
of hepatitis B vaccine and of treatment of 
the mother to prevent further hepatitis B 
transmission are required to achieve impact 
by 2030. In addition, there are massive 
gaps in hepatitis B diagnosis and treatment, 
including among the populations most 
severely affected and at higher risk.
• New data show that 9.4 million people are 
receiving treatment to cure chronic hepatitis 
C virus infection, an almost 10-fold increase 
from the baseline of 1 million at the end of 
2015. This scale-up of treatment has been 
sufficient to reverse the trend of increasing 
mortality from hepatitis C for the first time. 
In Egypt, universal access to treatment has 
resulted in declining mortality and incidence. 
However, improved data show that the 
number of people dying from hepatitis B 
and C worldwide still remains daunting at 
1.1 million per year.
As the global health sector strategies 
for HIV, viral hepatitis and sexually 
transmitted infections (STIs) 
2016–2021 near the end of their 
implementation period, this report 
provides accountability for the main 
achievements and gaps to date and 
highlights actions to take forward 
towards eliminating these diseases 
as public health threats by 2030. 
The report publishes new estimates 
for viral hepatitis with a threefold 
improvement in the completeness 
of reporting. It also publishes new 
estimates for the main STIs, providing 
a more accurate baseline to guide 
priorities in the forthcoming decade.
Global messages
Key messages
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• Two thirds of all living with HIV and 85% of 
pregnant women people living with HIV are 
receiving antiretroviral therapy, supporting 
a substantial decline in mortality related to 
HIV and AIDS. Treatment coverage in sub-
Saharan Africa is uniquely higher than global 
coverage because of sustained partner and 
country financing.
• The global response to STIs is gathering 
momentum after years of neglect. More 
countries have national strategic plans and 
updated guidelines to address STIs, and 
coverage of interventions such as syphilis 
screening of pregnant women in antenatal 
care and human papillomavirus vaccination, 
are increasing.
3. Yet many gaps remain. Most global 2020 
targets have been missed, and accelerated 
action is needed to reach the Sustainable 
Development Goals in the next decade.
• With an estimated 1.7 million people 
acquiring HIV in 2019, the number has fallen 
by 23% to the lowest since 2010. However, 
this remains far below the global target of 
less than 500 000 people newly infected by 
2020. Ending the global HIV epidemic will 
require stronger commitment to address the 
inequalities, stigma and discrimination that 
continue to drive the epidemic and prevent 
many people from accessing the services they 
need. This is the focus of the United Nations 
High Level meeting on HIV in June 2021.
• New data show that hepatitis B and C 
cause 1.1 million deaths and 3.0 million 
new infections per year. Only 10% of people 
who have chronic infection with hepatitis 
B virus are diagnosed, and 22% of which 
receive treatment. For hepatitis C infection, 
21% of people are diagnosed and 62% of 
those diagnosed receive treatment. Price 
reductions have made hepatitis C treatment 
an affordable high-impact intervention, but 
coverage needs to increase nearly sixfold in 
the next decade to reach the 2030 targets 
for elimination.
• New data on STIs show 374 million new 
cases per year. Other than slow declines in 
congenital syphilis, the incidence of most 
other STIs is plateauing despite ambitious 
targets. There is a major need to boost 
synergistic efforts to prevent and treat STIs, 
including HIV, among adolescent girls and 
young women and key populations. Global 
commitment, funding and an integrated 
public health approach are essential to bend 
the curve for these infections.
• Although an increasing number of countries 
are organizing strategies and planning 
frameworks across HIV, viral hepatitis 
and STIs, most are missing important 
opportunities to integrate and link services 
and responses to provide people-centred 
services that also leverage efficiency at the 
primary health care and health system levels.
4. Stigma and inequalities facing the 
populations most vulnerable and at risk 
have to be addressed across all diseases to 
reach the Sustainable Development Goals. 
Key populations (including gay men and 
other men who have sex with men, people 
who inject drugs, sex workers, transgender 
people and prisoners) and their partners 
account for 62% of the people acquiring HIV. 
Viral hepatitis disproportionately affects 
those who are economically disadvantaged, 
displaced people and migrants and rural 
populations. Further, injecting drug use is a 
major contributor to the number of people 
newly infected with hepatitis C globally. 
Many of these population groups overlap 
with groups recognized as especially 
vulnerable to STIs. Access to prevention, 
harm reduction and health-care services 
for these populations is largely insufficient, 
and persistent stigma, inequalities, 
criminalization and other sociostructural 
barriers are preventing response efforts from 
reaching the people who need them most.
6. Regional differentiation in implementing 
the strategies has amplified progress. 
In the next stages, further granular and 
differentiated approaches should be 
developed by region, epidemic status and 
population to ensure that targets are reached 
in all settings and that no one is left behind. 
Chapter 4 of this report present dedicated 
regional messages.
5. New WHO data show that HIV testing and 
prevention, as well as Hepatitis B and C 
services, are among the most frequently 
disrupted services caused by COVID-19. 
HIV treatment, as well as STI services have 
also experienced disruption. The COVID-19 
pandemic has forced all three disease 
programmes to innovate to deliver and 
maintain essential health services safely 
within community-led, community-based and 
differentiated models of care.  
Making full use of such people-centred 
and community-led innovations can 
further enable countries to fully leverage 
the capacity of health and community 
systems and respond to the needs of the 
most vulnerable people in an equitable and 
sustainable manner.
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7. Better data, greater focus on solutions to 
address gaps in prevention, treatment and 
delivery and renewed advocacy and demand 
creation will be needed to reach the 2030 
Sustainable Development Goal targets. This 
report identifies 10 cross-cutting priority areas 
that must be strengthened across HIV, viral 
hepatitis and STIs to accelerate impact by 2030. 
They cover actions updated since 2018 based on 
successes and gaps for each of the five strategic 
directions. They also include new actions that 
align with the WHO Triple Billion targets to 
address social and structural determinants of 
these infections, promote joint management 
across diseases and draws on lessons from the 
COVID-19 pandemic to strengthen community 
engagement and service delivery.
1. Leverage common people-centred and 
disaggregated data platforms, including 
strengthening digital health data and building 
capacity to analyse and use data for improving 
programmes.
2. Scale up point-of-care diagnostics, self-testing 
and self-collection to reach everyone who is 
vulnerable, at higher risk and hard to reach, 
including key populations, infants and children 
and men who are not engaged in care; continue 
to simplify testing and treatment and improve 
links so that those already diagnosed can 
receive care rapidly.
3. Achieve triple elimination of mother-to-child 
transmission of HIV, hepatitis B virus and 
syphilis and explore the expansion of the 
elimination focus to eliminating infection among 
children for the next phase of the global health 
sector strategies.
4. Improve access to drugs and diagnostics by 
further reducing prices, including integrating 
costs in national health and domestic financing.
5. Innovate to maximize the use of differentiated 
and people-centred service delivery options 
across HIV, viral hepatitis and STIs to tailor and 
deliver services according to people’s needs 
and preferences and train and empower more 
health-care workers to provide treatment where 
the availability of specialists is limited.
6. Innovate to strengthen community 
engagement, community-based service 
delivery and community-led monitoring in the 
context of primary health care.
7. Protect against the threat of antimicrobial 
resistance and other risks, including disruption 
of services because of COVID-19 and other 
global health emergencies.
8. Strengthen joint responses for HIV, viral 
hepatitis and STIs with TB and other key 
comorbidities by further aligning programme 
management, service delivery and monitoring to 
support universal health coverage.
9. Integrate sexual and reproductive health and 
rights into existing programmes, raise the 
profile of STIs and reinvigorate the emphasis on 
primary prevention.
10. Address social and structural determinants 
that impact vulnerability and access to 
services and tackle the stigma, discrimination, 
criminalization and inequalities that undermine 
the response.
Regional differentiation, progress and gaps
• The African Region leads the way in HIV testing 
and treatment and has the opportunity over 
the next decade to extend this to addressing 
hepatitis B and C virus and to syphilis 
transmission from mother to child in order 
to dramatically reduce the high burden of 
communicable diseases in the Region.
• The Region of the Americas has led approaches 
to advance the triple elimination of mother-to-
child transmission of HIV, hepatitis B and syphilis 
and to deliver services along the cascade for key 
populations. Over the next decade, they need to 
systematically fill gaps in the HIV, viral hepatitis 
and STI service cascades to leave no one behind.
• The South-East Asia Region has some of the 
world’s leading programmes for key populations 
and community-based responses. Three 
countries in the Region have been validated for 
EMTCT of HIV and syphilis and four countries 
have been certified to have achieved hepatitis 
B control through immunization. Progress in 
the response to HIV and STIs has nevertheless 
plateaued. Financing for HIV, viral hepatitis 
and STIs needs to be sustained and expanded 
towards universal health coverage.
• In the European Region, gaps in testing and 
treatment for HIV, viral hepatitis and STIs need  
to be filled rapidly. There have been major 
advances in hepatitis programme planning, but 
the estimated number of people acquiring HIV 
has been increasing.
• The Eastern Mediterranean Region leads the way 
in scaling up testing and treatment for hepatitis 
C virus, accounting for 37% of the global total 
number diagnosed and 52% of the global number 
of people treated in 2019. Some countries have 
an opportunity to move towards elimination. The 
impact of these population-based approaches 
needs to be expanded and transferred to ensure 
that nobody is left behind in access to hepatitis B, 
STIs and HIV services.
• The Western Pacific Region has made major 
progress in expanding access to services for 
hepatitis B and C virus, largely because of 
domestic funding and substantial drug price 
reductions. There is an opportunity to include viral 
hepatitis, HIV and STIs in national health financing.
The lessons from the COVID-19 response provide a 
historical opportunity to foster greater solidarity and 
innovation in the response to communicable diseases 
over the next decade. Disease-specific responses 
and the goals of universal health coverage and global 
health security are mutually reinforcing and need to 
be advanced together. By taking decisive action now, 
we can prevent 2 million people from losing their lives 
each year and emerge stronger from the challenge of 
COVID-19 to reach the Sustainable Development Goals 
by 2030.
The HIV responses of the health sector must be 
strongly aligned with the Global AIDS Strategy 2021–
2026, developed by UNAIDS with support from WHO. 
It also provides clear opportunities for synergy for 
the responses focused on viral hepatitis and STIs. 
The focus of the Global AIDS Strategy on addressing 
inequalities to end AIDS as a public health threat 
provides an important framework for all communicable 
diseases alongside the Strategy’s three interlinked 
priorities: maximizing equitable and equal access to 
HIV services and solutions; breaking down barriers 
to achieving HIV outcomes; and fully resourcing and 
sustaining efficient HIV responses and integrating them 
into systems for health, social protection, humanitarian 
settings and pandemic responses.
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A backdrop of crisis,
resilience and innovation
HIV, viral hepatitis and sexually transmitted infections (STIs) account 
for 2.3 million deaths per year, which represents 14% of deaths from 
infectious and parasitic diseases, digestive diseases and cancer and 
4% of deaths from all causes worldwide (1). They result in 1 million 
people newly infected per day and 1.2 million people developing cancer 
per year and continue to be a major public health burden in terms of 
mortality, morbidity and quality of life. These communicable diseases 
share common modes of transmission and determinants and call for 
a common public health approach along the continuum of prevention, 
diagnosis, treatment and care. Nevertheless, there are key differences 
in their status in 2020, with important lessons to learn among these 
diseases and joint opportunities to achieve universal health coverage.
people develop cancer each 
year due to viral hepatitis, 
STIs and HIV 
1.2m
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In 2016, WHO Member States adopted three aligned global health 
sector strategies on HIV, viral hepatitis and STIs, respectively, 
to guide actions over the period 2016–2021 towards eliminating 
them as public health threats by 2030. The strategies share a 
common goal to progress towards universal health coverage, 
a key priority of WHO’s Thirteenth General Programme of Work 
2019–2023 and the 2030 Agenda for Sustainable Development 
(2,3). The strategies are organized around a common framework 
that promotes synergy across the diseases and with other 
programmatic health priorities.
This is the second combined progress report on implementation 
of these strategies, following the mid-term review of progress at 
the end of 2018 (4). At the time, the pace of progress was uneven 
and insufficient to meet global targets by 2030. The number of 
people dying from HIV-related causes was declining with growing 
access to treatment, but the number of people newly acquiring 
HIV was not falling rapidly enough. The global response to 
hepatitis B and C virus was gaining momentum, but access to 
testing and treatment remained far below needs, and mortality 
was increasing. The global response to STIs was in crisis after 
years of neglect, highlighting an urgent need to revitalize STI 
prevention. Key and vulnerable populations were not adequately 
reached with essential interventions, and many opportunities for 
joint action were being missed. The report called for accelerating 
progress with integrated and people-centred approaches to end 
the epidemics as public health threats by 2030.
Since the strategies are now in their final year of implementation, 
this report takes stock of achievements and gaps, globally and by 
region, at the end of 2020, and highlights action to take forward to 
the new decade towards elimination by 2030. It also provides new 
estimates on the disease burden of viral hepatitis and STIs, which 
will enable a more informed global response as part of the next 
phase of strategies for the period 2022–2030.
Further, this review comes at a critical moment when the 
COVID-19 pandemic has placed an enormous strain on health 
systems and financing worldwide and exposed their weaknesses 
and inequalities. The report provides an opportunity to assess 
the initial impact of COVID-19 and draw lessons from the global 
response. The lessons from COVID-19 and the innovations 
demonstrated by health and community systems to maintain 
essential services during a crisis are highlighted throughout the 
report.
©WHO/Andre Rugema
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Impact
Targets (by 2020) Status
• Reduce the annual number of people dying from HIV-related 
causes to less than 500 000 globally by 2020
• 690 000 [500 000–970 000] people died from HIV-related causes 
globally in 2019
• Reduce the number of people living with HIV dying from 
tuberculosis (TB)-related causes by 75% by 2020
• 208 000 [177 000–242 000] people living with HIV died from  
TB-related causes in 2019
• Reduce the number of people living with HIV dying from 
hepatitis B– and C–related causes by 10%, in accordance with 
the mortality targets for all people with chronic hepatitis B and 
C infection
• No data
• Reduce the annual number of people acquiring HIV infection to 
less than 500 000 by 2020
• 1.7 million [1.2 million–2.2 million] people acquired HIV infection in 
2019
• Zero new infections among children (0–14 years old) by 2020 • 150 000 [94 000–240 000] children acquired HIV infection in 2019
Service coverage
• Ensure that 90% of people living with HIV know their HIV status • 81% [68–95%] of people living with HIV knew their HIV status 
globally in 2019. 
• Ensure that 90% of the people who know their HIV-positive 
status receive antiretroviral therapy
• 82% [66–97%] of those who knew that they were HIV-positive were 
accessing treatment in 2019
• Ensure that 90% of people living with HIV receiving treatment 
have suppressed viral loads
• 88% [71–100%] of people receiving treatment had suppressed viral 
loads in 2019
 
Annex 1 provides a complete set of global and regional data and sources.
HIV
Table 1 presents the impact and service coverage targets of the 
global health sector strategies for HIV, viral hepatitis and STIs 
2016–2021 and provides an update on the achievement of these 
targets by the end of 2020.
Table 1. Global health sector strategies for HIV, viral hepatitis and STIs 2016–2021: 
targets and results
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Impact
Targets (by 2020 and 2030) Status
• 30% reduction in new cases of chronic viral hepatitis B and C 
infections by 2020, 90% reduction by 2030
• 1.5 million [1.1 million–2.6 million] people were newly infected with 
chronic hepatitis B infection in 2019
• 10% reduction in viral hepatitis B and C deaths by 2020, 65% 
reduction by 2030
• 1.5 million [1.3 million–1.8 million] people were newly infected with 
chronic hepatitis C infection in 2019
• 820 000 [450 000–950 000] people died from hepatitis B infection–
related causes in 2019
• 290 000 [230 000–580 000] people died from hepatitis C infection–
related causes in 2019
Service coverage
• 90% coverage of hepatitis B virus vaccine (third dose) by 2020 • 85% coverage of hepatitis B vaccine (third dose) in 2019
• 50% coverage of prevention of mother-to-child transmission of 
hepatitis B virus by 2020, 90% coverage by 2030
• 43% global coverage for timely birth dose of hepatitis B vaccine 
in 2019
• 95% of blood donations screened in a quality-assured manner 
by 2020, 100% screened by 2030
• Only baseline data available: 97% of donations screened with 
quality assurance in 2015
• 50% of injections administered with safety-engineered devices 
in and out of health facilities by 2020, 90% by 2030
• 3.9% reuse of injection equipment in 2017
• 200 sterile needles and syringes provided per person who 
injects drugs per year by 2020, 300 by 2030
• 33 syringes or needle sets per person who injects drugs per year 
in 2017
• 30% of chronic viral hepatitis B and C infections diagnosed by 
2020, 90% by 2030
• 30.4 million [24.3 million–38.0 million] people living with hepatitis B 
knew their hepatitis B status in 2019
• 80% of eligible people with chronic hepatitis B and C virus 
infection treated by 2030, respectively
• 6.6 million [5.3 million–8.3 million] people diagnosed with hepatitis B 
received treatment in 2019
• 15.2 million [11.2 million–19.0 million] people living with hepatitis C 
knew their hepatitis C status in 2019
• 9.4 million [7.5 million–11.7 million] people diagnosed with hepatitis C 
infection had been treated using direct-acting antiviral drugs between 
2015 and 2019
 
Annex 1 provides a complete set of global and regional data and sources.
Viral hepatitis
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Impact
Targets (by 2020 and 2030) Status
• 90% reduction of Treponema pallidum incidence globally 
(2018 global baseline)
• 7.1 million [2.4 million–11.5 million] people were newly infected 
with T. pallidum in 2020
• 90% reduction in Neisseria gonorrhoeae incidence globally 
(2018 global baseline)
• 82.4 million [47.7 million–130.4 million] people were newly 
infected with N. gonorrhoeae in 2020
• 50 or fewer cases of congenital syphilis per 100 000 live 
births in 80% of countries
• 473 [385–561] congenital syphilis cases per 100 000 live births in 
2016, a decline of 12% in 4 years
• Sustain 90% national coverage and at least 80% in every 
district (or equivalent administrative unit) in countries with the 
human papillomavirus vaccine in their national immunization 
programme
• Of 75 countries surveyed, 19 (25%) reported >80% human 
papillomavirus vaccine coverage in 2019–2020
Service coverage, by 2020:
• 70% of countries have STI surveillance systems in place that 
are able to monitor progress towards the relevant targets
• 97 of 110 countries (87%) had STI surveillance or monitoring in 
place in 2019–2020
• 70% of countries have at least 95% of pregnant women 
screened for HIV and/or syphilis; 95% of pregnant women 
screened for HIV and/or syphilis with free, prior and informed 
consent; 90% of pregnant women living with HIV receiving 
effective treatment; and 95% of syphilis-seropositive pregnant 
women treated with at least one dose of intramuscular 
benzathine penicillin or other effective regimen
• 103 of 111 countries (93%) had policies for antenatal screening 
and treatment of syphilis in 2019–2020
• 70% of key populations for HIV have access to a full range of 
services relevant to STIs and HIV, including condoms
• No data
• 70% of countries provide STI services or links to such services 
in all primary, HIV, reproductive health, family planning and 
antenatal and postnatal care services
• Countries provided link to STI services in other health services, 
such as primary health care (88%), HIV services (91%), 
reproductive health services (84%), family planning (77%) and  
pre- and postnatal services (89%) in 2019–2020
• 70% of countries deliver human papillomavirus (HPV) 
vaccines through the national immunization programme
• 59% of countries included the HPV vaccine in the national 
immunization schedule in 2019–2020
• 70% of countries report on antimicrobial resistance in N. 
gonorrhoeae
• 64% of countries conducted surveillance of gonococcal 
antimicrobial susceptibility in 2019–2020
 
Annex 1 provides a complete set of global and regional data and sources.
Sexually transmitted infections










































HIV incidence critically 
behind the targets; 
mortality reduced, but 
unacceptably high
One of the first 
areas to reach the 
health Sustainable 
Development Goal 
targets for 2020, 
but huge gaps in 
diagnosis remain
Trends in STIs 
plateauing and far 
behind targets, 
despite some 
progress in reducing 
congenital syphilis
Impact
Figure. 1 presents the accountability ratings for progress 
achieved under each of the global health sector strategies, 
towards impact and service coverage targets and towards 
implementing the priority actions under each of the five 
strategic directions of the strategies.
Fig. 1. Accountability for the global health sector strategies 2016–2021: 
summary scorecard
Major increase in hepatitis C 
treatment affecting mortality 
but need to rapidly accelerate 
hepatitis B and C diagnosis
Major progress in 
reducing mother-to-child 
transmission of syphilis but 
critical gaps in STI diagnosis
Major progress towards  
90–90–90 targets, but gaps for 
key populations and many regions
Dark green Light green Yellow Orange Red
On track On track with gaps Incomplete but major progress Incomplete, minor progress No progress
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Together, HIV, viral hepatitis and 
STIs form a cluster of interlinked 
communicable diseases with 
common determinants of health, 
modes of transmission and high 
rates of coinfection, especially 
among populations most severely 
affected and at higher risk.
This report publishes new estimates for hepatitis B and C 
viruses and for the four main STIs, providing a more accurate 
baseline for the forthcoming decade of progress towards 
eliminating them by 2030.
Viral hepatitis accounts for a significant global disease burden 
and high mortality from liver cancer and cirrhosis. In 2019, 
296 million people were living with chronic hepatitis B virus 
infection and 58 million people with chronic hepatitis C virus 
infection worldwide. New estimates show that about 1.5 million 
people newly acquire hepatitis B infection each year, despite 
the availability of a highly efficacious vaccine. About 1.5 million 
people newly acquire hepatitis C virus infection. Viral hepatitis 
caused 1.1 million deaths in 2019, 96% of which were caused 
by hepatitis B and C virus (5). Most of these deaths result from 
chronic liver disease and liver cancer. The greatest burden 
of hepatitis B and C infection is concentrated by geography 
and population, with 80% of the global burden of hepatitis C 
infection in the 10 most severely affected countries. People 
from economically disadvantaged regions, displaced people 
and migrants, and rural populations are more severely affected. 
Further, injecting drug use is a major contributor to the hepatitis 
C epidemic globally (6). Other affected population groups 
include health-care workers exposed through needle-stick 
injuries, people in prisons and closed settings, and gay men 
and other men who have sex with men.
STIs are defined by multiple neglected pandemics that cause a 
significant global disease burden. More than 1 million curable 
STIs are acquired every day worldwide, primarily caused by 
Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema 
pallidum (syphilis) and Trichomonas vaginalis (7). This report 
published new estimates for four curable STIs that indicate 
a global incidence of 374 million new cases of these STIs, 
including 128 million chlamydia cases; 82 million gonorrhoea 
1.1 Major epidemics with 
lessons across diseases
cases; 156 million trichomoniasis cases; and 7 million syphilis 
cases each year. In addition, previous data indicate that more 
than 1 in 7 women is estimated to have HPV infection, and 
more than 500 million people have genital herpes simplex virus 
(HSV) infection (8–10). Population groups that are especially 
vulnerable to STIs include sex workers and their clients, gay 
men and other men who have sex with men, transgender people, 
young adults and adolescents, mobile populations and people 
affected by conflict and civil unrest (11). A first systematic 
review and meta-analysis of the global prevalence of syphilis 
among gay men and other men who have sex with men found 
that the global pooled prevalence from 2000 to 2020 was 7.5% 
versus 0.5% among men in the general population (12). The 
global health sector strategy focuses on three STIs that require 
immediate action for control – N. gonorrhoeae infection,  
T. pallidum infection with the elimination of congenital syphilis,  
and HPV infection.
An estimated 38 million people were living with HIV worldwide 
in 2019. A total of 1.7 million people acquired HIV in 2019 
alone, and 690 000 people died from HIV-related causes. Key 
populations (including men who have sex with men, people who 
inject drugs, sex workers, transgender people and prisoners) 
and their partners accounted for 62% of the people newly 
infected worldwide, including the largest share of people 
acquiring HIV in nearly all regions (13). About 5500 adolescent 
girls and young women (15-24 years old) acquire HIV each week, 
and in sub-Saharan Africa, they are twice as likely to acquire 
HIV as adolescent boys and young men (14). HIV is a major STI 
and shares behavioural, social and structural determinants with 
other STIs.
More than 2.3 million 
lives lost each year
2.3m
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Total deaths caused by 
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Sources: Overall burden of disease: WHO Global Health Estimates [website] (1). HIV: 
UNAIDS/WHO, 2020. Hepatitis: WHO, 2021. HPV-related cervical cancer: International 
Agency for Research on Cancer and WHO, 2021. STIs: Korenromp et al. (15). 
Fig. 2. Deaths related to HIV, viral hepatitis and STIs among all deaths related 
to infectious and parasitic diseases, digestive diseases, and cancer, 2019 
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Fig.3. New cases of four curable STIs among adults (15–49 years old) 
per year, by sex, global, 2020
Fig. 4. New cases of HIV, hepatitis B infection and hepatitis C virus 


























































new STI infections 
each day
1m
1. A backdrop of crisis, resilience and innovation 11
Table 2. New cancer cases attributable to HIV, viral hepatitis and STIs, 2018
Disease New cases
Hepatocellular carcinoma caused by hepatitis B and C 500 000
Cervical cancer caused by HPV 570 000
Other types of cancer caused by viral hepatitis and HPV 140 000
Total 1 210 000
Source: Martel et al. (16).
Table 3. Coinfections and comorbidities related to HIV, viral hepatitis, 
STIs and other major infectious diseases
Diseases Summary of the evidence
HIV and viral hepatitis 2.7 million people are coinfected with HIV and hepatitis B virus (2015) (5).
2.3 million people are coinfected with HIV and hepatitis C virus (2015) (5).
HIV and viral hepatitis Among people living with HIV, untreated hepatitis coinfection promotes more rapid 
progression of hepatitis B– and/or C–related liver disease, hepatocellular cancer 
and untimely death, undermining the gains of effective HIV treatment.
HIV coinfection doubles the risk of mother-to-child transmission of viral hepatitis (5). 
More than half of all people coinfected with HIV and hepatitis C are people who 
inject drugs.
Men living with HIV who have sex with men are at substantially higher risk of 
hepatitis C infection (17).
HIV and all STIs The presence of untreated STIs can increase the risk of becoming infected with HIV 
by a factor of up to 10 (18).
HIV and HSV type 2 (HSV-2) HSV-2 infection resulted in an estimated 420 000 [317 000–546 000] of the 1.4 
million people 15–49 years old acquiring HIV through sexual transmission (2016) (8).
HIV and human papillomavirus (HPV) HIV enhances HPV-induced carcinogenesis, and women living with HIV have a six-fold 
risk of cervical cancer versus HIV-negative women (19).
28 000 [20 000–36 000] new cervical cancer cases are attributable to HIV infection 
(2018) (19).
HIV and TB 208 000 [177 000–242 000] people living with HIV died in 2019 from HIV with TB as 
a contributory cause of death.
815 000 [729 000–906 000] people living with HIV develop a new TB case (2019) (20).
HIV and COVID-19 Preliminary evidence suggests that people with HIV have increased risk of poor 
outcomes with COVID-19 (21).
Interlinked diseases with common 
determinants and coinfections
new cancer cases  
each year
1.2m
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Diverse epidemics by WHO Region
Fig. 5. Number of people acquiring HIV and number of people dying 
from HIV-related causes, 2019
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Fig. 6. Hepatitis B and C new infections and mortality by WHO region, 2019
WHO REGIONS
African Region
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Fig. 7. Incident cases of four curable STIs among adults (15–49 years old), 
by WHO region, 2020
WHO REGIONS
African Region






























Fig. 8. Estimated age-standardized incidence of cervical cancer, all ages, 2020
Source: WHO, 2021.
ESTIMATED AGE-STANDARDIZED








Sources: International Agency for Research on Cancer and WHO, 2021.
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Uneven distribution by population
Fig. 9. Prevalence of sexually transmitted infections among adults 
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Fig. 10. Members of key populations acquiring HIV, global, 2019
Sex workers
8%




Clients of sex workers





* Data only included from Asia and the Pacific, the Caribbean,
eastern Europe and central Asia, Latin America, and western and
central Europe and North America.
Gay men and other
men who have sex
with men
23%
Source: UNAIDS special analysis, 2020.
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Global efforts to eliminate HIV, 
viral hepatitis and STIs required 
acceleration to achieve targets even 
before the COVID-19 pandemic. As 
countries worldwide mobilized efforts 
to mount a comprehensive public 
health response to a new infectious 
disease, the fact that global health 
security would not be achieved 
without resilient, adaptable and 
equitable health systems to deliver 
universal health coverage became 
more evident than ever.
The response to the pandemic, with stay-at-home measures, 
travel restrictions, physical distancing requirements and  
supply chain interruptions, disrupted essential health services  
in many places and threatened to halt or reverse the progress 
achieved so far. In the first round of the WHO pulse survey  
on the continuity of essential services during the COVID-19 
pandemic conducted between May and September 2020,  
nearly all the 105 reporting countries faced some disruption  
of essential health services as a result of the pandemic (22).
Services for HIV, viral hepatitis and STIs were also affected.  
In June 2020, 34 countries reported disruption in antiretroviral 
therapy delivery. A study on how COVID-19 affected harm-
reduction services in seven countries in Asia found sudden 
declines between April and June 2020 in needle and syringe 
distribution and in HIV testing for people who inject drugs, with 
some recovery from July 2020 onwards (23). The evidence on 
how COVID-19 has affected reported STI cases is mixed. The data 
available are mostly from high-income countries and suggest in 
some places and among some populations that fewer STIs may 
have been diagnosed in 2020 than in 2019 (24–30). This may 
result from interruptions to STI testing services. Fully assessing 
the impact of COVID requires generating additional clinical, 
epidemiological and psychosocial data on the behavioural links 
between COVID-19 and HIV, viral hepatitis and STIs.
1.2 Disruption and opportunities 
arising from COVID-19
Essential health services began to resume by the second half 
of 2020, but there is no room for complacency. Countries 
have continued to face challenges as they faced new waves 
of increasing COVID-19 transmission at the end of 2020. 
Preliminary findings from the second round of the WHO pulse 
survey conducted between December 2020 and March 2021 
show that, despite evidence of resilience and innovation to 
restore some services, disruption to essential health services is 
still geographically widespread, and 94% of reporting countries 
experienced some disruption. On average, 36% of countries 
reported disruption to communicable disease services (31).
HIV testing services and thus antiretroviral therapy initiation 
have also continued to be affected in many countries. In the 
second round of the WHO pulse survey, 49% of countries 
reported some disruption to HIV testing and 46% to HIV 
prevention. The number of countries showing disruption in 
antiretroviral therapy delivery declined from 34 in June 2020 
to 17 by March 2021, but one quarter of the reporting countries 
continued to face disruption in newly initiating treatment. 
Similarly, 43% of countries reported disruption in hepatitis B and 
C diagnosis and treatment (31).
This disruption results from a mix of supply- and demand-side 
factors, and their extent can differ within a country in terms of 
service delivery, population or geography. In some places, HIV 
testing services, especially community and voluntary testing 
activities, have been limited or restricted. Demand for services 
has also declined as a result of physical distancing measures, 
financial constraints or fear of contracting COVID-19. Some 
countries now face the double challenge of mitigating the risk of 
further disruption while having to catch up on disruption that has 
already taken place. Ongoing efforts are needed to focus and 
set priorities among interventions while planning for strategic 
efforts to prevent going further off-track from achieving the 
global goals.
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Fig. 11. Percentages of countries reporting disruptions across tracer service 
areas, January - March 2021 
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Mental, neurological and substance use disorders (n = 121)
Neglected tropical diseases (n = 109)
Noncommunicable diseases (n = 121)
Immunization (n = 112)
Communicable diseases (n = 128)
Reproductive, maternal, newborn, child and
adolescent health and nutrition (n = 121)
Denominator excludes “Not applicable” or “Do not know” responses.
Source: Second round of the national pulse survey on continuity of essential health 
services during the COVID-19 pandemic: January–March 2021 (31).
Fig. 12. Number of countries reporting disruption in antiretroviral therapy 
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Source: WHO HIV, hepatitis and sexually transmitted infections survey, 2021. 
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Fig. 13. Disruption in other services for HIV and viral hepatitis, March 2021 
Fig. 14. Disruption in antiretroviral therapy services caused by COVID-19 by WHO 
region, March 2021 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
HIV prevention services (n = 111)
HIV testing services (n = 111)
Continuation of established ARV treatment (n = 115)
Initiation of new ARV treatment (n = 111)
Hepatitis B and C diagnosis and treatment (n = 107)
More than 50% 26-50% 5-25% Less than 5% Do not know Not applicable
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
More than 50% 26-50% 5-25% Less than 5% Do not know Not applicable
African Region (n = 37)
Region of the Americas (n = 23)
South-East Asia Region (n = 11)
European Region (n = 18)
Eastern Mediterranean Region (n = 17)
Western Pacific Region (n = 9)
PULSE survey results only: in case of exclusion of “Not applicable” or “Do not know” responses in the denominator, the percentages of 
countries reporting disruptions (i.e. ≥5%) are as follows: HIV testing services (49%), HIV prevention services (46%), Hepatitis B and C 
diagnosis and treatment (43%), Initiation of new ARV treatment (25%) and Continuation of established ARV treatment (17%).
For more information on the PULSE survey: https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS-continuity-survey-2021.1.
Sources: WHO HIV, hepatitis and sexually transmitted infections survey, 2021 and  
Second round of the national pulse survey on continuity of essential health services  
during the COVID-19 pandemic: January–March 2021 (31) (consolidated data).
Sources: WHO HIV, hepatitis and sexually transmitted infections survey, 2021 and 
Second round of the national pulse survey on continuity of essential health services 
during the COVID-19 pandemic: January–March 2021 (31) (consolidated data).
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Worldwide, countries and communities facing the COVID-19 
pandemic have responded in innovative ways to adapt, combine, 
differentiate, decentralize and simplify health services to meet 
people’s needs during the crisis.
• Accelerating policy implementation. Many countries 
worldwide were able to implement existing policies to provide 
multimonth supplies of antiretroviral medicines to people 
who did not have access to health facilities. This improved 
patient security by ensuring continuity of HIV treatment 
but also required adequate antiretroviral drug stocks. Other 
programmes followed suit and provided opioid substitution 
therapy and other treatments for multiple months (32).
• Leveraging health systems capacity. In sub-Saharan Africa, 
countries used existing HIV and TB laboratory infrastructure, 
sample transportation, quality assurance mechanisms and 
staff to provide COVID-19 testing, although in some cases 
this led to delays in testing for other diseases in the early 
phase of the response (32).
• Simplifying community-based delivery. In the South-
East Asia Region, countries shifted service delivery from 
facilities to communities, providing take-home doses of 
opioid substitution therapy to people who inject drugs, home 
delivery of antiretroviral medicines for people unable to 
reach facilities, delivering pre-exposure prophylaxis (PrEP) 
through communities, introducing telehealth consultations 
and training HIV teams, including virtually, on COVID-19 
prevention and management (33,34).
• Developing strategies for safe delivery. In sub-Saharan 
Africa, programmes delivering voluntary medical male 
circumcision developed safer and more targeted mobilization 
strategies. For example, in Uganda, a voluntary medical male 
circumcision programme got back on track to meet its goals 
by using strategies such as placing branded handwashing 
stations in dense urban areas to support COVID-19 
prevention efforts and emphasize that voluntary medical 
male circumcision services remained available, restarting 
outdoor-only, masked door-to-door mobilization, and 
employing community educators to deliver both COVID-19 
awareness and messages promoting voluntary medical male 
circumcision (35).
• Expanding the use of self-care interventions. A project in 
Bulgaria provided HIV self-testing and telemedicine to key 
populations. Supported by a vast social media campaign 
to disseminate information, the initiative helped to reach 
men who have sex with men and transgender people with 
HIV testing without having to visit a health facility (36). A 
dedicated phone line was also available for follow-up. HIV 
self-testing has also been expanded in many countries in the 
African Region, Asia and the Americas.
• Increasing the use of digital health. In the Region of the 
Americas, a project delivering PrEP to young key populations 
in Brazil adapted its approach during the COVID-19 pandemic 
by using telehealth, social media and an artificial intelligence 
chatbot to recruit participants and provide information and 
peer support. The team also provided discrete home delivery 
of condoms, lubricants, self-tests for HIV and medicines for 
PrEP (37).
The pandemic has demonstrated the importance and 
effectiveness of making full use of such people-centred 
and community-led solutions to deliver essential services 
in an equitable and sustainable way. Maintaining these 
innovative approaches as part of a catch-up of services can 
enable countries to fully leverage the resilience of health 
and community systems and respond to the needs of the 
most vulnerable people in the path towards the Sustainable 
Development Goals.
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Box 1.  
HIV is a risk factor for illness severity among people hospitalized with 
COVID-19
Preliminary analysis of clinical data of people hospitalized 
with suspected or confirmed COVID-19 infection suggests 
that HIV appears to be an independent risk factor for illness 
severity and for in-hospital mortality.
The data submitted from 24 countries between January 
2020 and March 2021 show that 46% (2638 of 5733) of 
people living with HIV hospitalized with suspected or 
confirmed COVID-19 had one or more underlying conditions 
at admission. Eight per cent were reported to be coinfected 
with TB (current or previous). Of the people living with 
HIV who were hospitalized with suspected or confirmed 
COVID-19 infection, 20% died during the hospital stay. 
These data were collected as part of the WHO Global 
COVID-19 Clinical Platform, a global initiative to expand the 
understanding of clinical characteristics and prognostic 
factors of people hospitalized with COVID-19 and to inform 
optimal clinical management. Through a secure web-based 
database, the initiative is collecting individual anonymized 
clinical data for people hospitalized with suspected or 
confirmed COVID-19 from health facilities worldwide (38).
WHO is continuing to expand the collection and analysis 
of clinical data of people hospitalized with and without 
HIV through the WHO Global COVID-19 Clinical Platform to 
improve the understanding of the clinical characterization 
and management impact of people hospitalized with 
COVID-19.
Fig.15. Outcomes among people living with HIV hospitalised with COVID-19, 




















Hospitalized cases from 35 countries submitted to WHO Global Clinical Platform for COVID-19 as of March 17, 2021.
N = 5810 of 67 372 (8.6%) with a recorded HIV status were reported as HIV positive.
90.8% (5275/5810) of the people living with HIV were reported from the WHO African Region.
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Box 2.  
Methods and data sources
The information presented in this report is compiled from 
several sources. The main sources and methods are 
summarized below. Annex 2 provides full details.
Disease burden
This report presents updated disease burden estimates for 
viral hepatitis B and C and for the four main curable STIs 
to account for the current status and provide a baseline for 
the next strategy. Global estimates for viral hepatitis are 
derived from global reporting, with a threefold increase from 
42 in 2018 to 130 in 2019, in the completeness of reporting 
compared with the previous report. Countries and partners 
validated the data, to ensure updated data on disease burden 
and on the diagnosis and treatment service cascade. Data 
were validated for 130 countries representing 93% of the 
disease burden and partner data (from the CDA Foundation, 
Institute for Health Metrics and Evaluation, Imperial College, 
University of Bristol and WHO) was validated by regions and 
countries where there are gaps. For STIs, global and regional 
estimates for chlamydia, gonorrhoea, trichomonas and 
syphilis were derived using systematic reviews applying the 
same methods as in 2012 (39) and 2016 (40).
Service coverage and policy uptake
HIV service coverage data have been obtained through 
the Global AIDS Monitoring System validated by countries, 
regions and globally. Data for viral hepatitis are derived from 
the Global Reporting System for viral hepatitis, validated by 
countries, regions and partners. Data on STIs are derived from 
a WHO country survey on implementation of STI strategies 
conducted in 2019 completed by 112 countries (41).
Impact of COVID-19
The data on HIV, viral hepatitis and STIs are complemented 
by data from successive WHO pulse surveys on continuity 
of essential health services during the COVID-19 pandemic, 
conducted between May and September 2020 and December 
2020 and March 2021. Further, detailed data were also 
collected for HIV, viral hepatitis and STI service disruption. 
Additional data on the impact of COVID-19 from global and 
country-level partners and published literature are also used 
where relevant.
Accountability scores
Each global health sector strategy defines fast-track priority 
actions for implementation by countries and for WHO. To 
assess progress achieved in implementing the global health 
sector strategies, documented evidence for completion of 
each action was reviewed to identify outstanding action and 
explanations. Based on this review of the completion rate 
of actions as defined in the strategies, each disease area 
and strategic direction was rated using a five-point scale of 
traffic-light colours:
• Dark green: on track, with minor gaps.
• Light green: on track, with few major gaps such as for 
specific populations, locations or interventions.
• Yellow: incomplete, but major efforts underway.
• Orange: incomplete, with only minor efforts underway.
• Red: no progress.
Using the ratings published in the 2019 mid-term report as 
a baseline, this report updates the ratings using the latest 
available data as of the end of 2020. The method used in 
the 2019 mid-term report is reapplied for these updates. 
The actions are first scored individually, either by analysing 
results against targets where quantifiable targets are 
available or using information on the delivery of the priority 
actions. Progress by strategic direction is then derived 
by aggregating the individual scores. This report also 
identifies priority actions to address underperforming areas. 
Specifically, it focuses on actions that had not been achieved 
at mid-term, assesses progress since then and documents 
the corrective actions undertaken.
Independent expert review
The report also draws on expert opinions from the WHO 
Strategic and Technical Advisory Committee on HIV and 
Viral Hepatitis (STAC-HIVHEP) and WHO partners working 
on STIs. This external advisory group, comprised of expert 
individuals from all WHO regions and key stakeholder 
constituencies, provides independent strategic and technical 
advice on WHO’s programme of work. At a meeting held at 
the end of 2020, they reviewed achievements of the 2016–
2021 global health sector strategies and identified gaps to 
address for developing the next strategies.
The data presented in this report have some 
limitations
Although the global health sector strategies cover the period 
2016–2021, it was considered important to conduct this 
review at the start of the final implementation year to inform 
the development of the new strategies during 2021 and 
incorporate lessons learned from the COVID-19 pandemic. 
The analysis of progress and gaps in this report therefore 
primarily reflects data for 2019, collected during 2020 and 
available by the first quarter of 2021. Updated data from 
2021 have been used where available, in particular to reflect 
the new disease burden estimates for viral hepatitis and STIs 
and to incorporate the latest information on the impact of 
COVID-19 on HIV, viral hepatitis and STI services. There has 
been a considerable country, regional and partner effort to 
improve the data in this report, especially for viral hepatitis 
reporting, with completeness increasing from 42 to 130 
countries. This provides a more reliable baseline on gaps 
to fill during the next strategy, but confidence limits need to 
be considered in interpreting trends over time because of 
increased accuracy in the data. Using all available data, the 
report provides a review of all impact and service delivery 
targets in the strategies as well as the actions proposed at 
the start of the strategy by strategic direction. In addition, it 
includes a special focus on actions not achieved mid-term 
and whether catch-up actions have been implemented.
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Box 3.  
A country survey to assess the implementation of the global health sector 
strategy for sexually transmitted infections 2016–2021
In 2019, WHO conducted a country survey among 194 
Member States to assess progress towards the targets of 
the global health sector strategy for sexually transmitted 
infections 2016–2021 (41). The data collected through 
this survey are presented in Table 1 and are also included 
in other sections of this report as relevant. They will also 
inform the development of the next phase of the strategy for 
the period 2022–2030.
Specifically, the survey sought to assess the achievement 
of the following 2020 milestones within the global STI 
strategy: (1) countries with a STI surveillance system in 
place; (2) countries with a national policy for universal 
screening of pregnant women for syphilis; (3) countries 
providing STI services or links to such services, (4) countries 
reporting on antimicrobial resistance of N. gonorrhoeae; 
(5) key populations with access to STI and HIV services; 
and (6) and countries including HPV vaccination within 
national immunization schedules. The survey also assessed 
programme service delivery and captured technical 
assistance needs in STI programming and surveillance.
Of the 194 Member States receiving the survey, 112 
returned a complete response. Overall, among these, 
64% reported having a national STI strategy, and a higher 
percentage reported having an STI surveillance system 
and providing STI services or links to such services in 
all primary, HIV, reproductive health, family planning and 
pre- and postnatal care services. Table 1 presents the 
results by indicator. Although the data suggest promising 
evidence that STI programming is being given priority in 
many reporting countries, they also reflect many gaps. For 
example, although STI surveillance systems may be in place, 
they mostly reflect case reporting based on syndromic 
diagnosis of the common STI clinical presentations. About 
96% of countries reported that HIV and syphilis testing 
was available for the general population, but far fewer 
countries reported the availability of testing for chlamydia, 
gonorrhoea, HPV and herpes. Although STI services may be 
available, the coverage and quality of these services may 
be lacking. The global strategy milestone target of 70% of 
countries having the HPV vaccine in national immunization 
schedules has not been met. Interpretation of all data must 
also consider reporting rates and reporting bias towards 
survey completion by countries with better-developed STI 
programming.
The survey provides important information for future priority 
setting and investments by countries, global stakeholders 
and international donors to bring the response to STIs back 
on track. Direct technical assistance was requested by 70% 
of surveyed countries to strengthen the STI response and 
will be needed to accelerate progress.
©John Rae
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Box 4.  
External review of progress in implementing the global health  
sector strategies
The STAC-HIVHEP meets biennially to provide the WHO Director-General with independent 
strategic and technical advice on WHO’s programme of work on the two epidemics. In 2020, 
the STAC-HIVHEP also addressed the STI epidemics. It comprises expert individuals from all 
WHO regions and key stakeholder groups, as appointed by the WHO Director-General.
In October 2012, the STAC-HIVHEP reviewed the global health sector strategies on HIV, viral 
hepatitis and STIs 2016–2021, focusing on elements to be highlighted in the forthcoming 
2022–2030 strategies.
The global responses to the HIV, viral hepatitis and STI 
epidemics are at different junctures.
Expanded access to HIV treatment has reduced the number 
of people dying from HIV-related causes to 690 000 per year, 
the lowest number since 1994, but prevention is progressing 
much too slowly with 1.7 million people acquiring HIV 
annually versus a target of less than 500 000. The 2020 HIV 
targets were not reached, and equity and financing gaps in 
the HIV response remain major concerns.
The incidence of viral hepatitis B and hepatitis C infection 
appears to be declining with 3 million people newly 
infected, especially for hepatitis B virus, with the 2020 
targets of the Sustainable Development Goals being 
reached, but massive testing and treatment scale-up are 
needed to reduce unacceptably high mortality of 1.1 million 
and reach the 2030 targets. There are major opportunities 
to prevent both hepatitis B and hepatitis C virus infections 
and to treat and cure hepatitis C virus infection.
Responses to the main STI epidemics are slowly gathering 
pace, but STI prevention, screening and treatment services 
are missing many of the estimated 374 million people who 
are living with at least one of four major STIs (N. gonorrhoeae, 
C. trachomatis, T. pallidum and T. vaginalis infection).
The STAC-HIVHEP strongly supported WHO’s commitment 
to pursue elimination targets for all three health strategies. 
Success, it said, requires stronger political will, adequate 
financing and ensuring that programmes reach populations 
at higher risk, including through stronger community 
engagement and by upholding people’s right to health. 
Greater health equity is a priority, and integration can be 
used to greater effect. The STAC-HIVHEP also called on 
WHO to support countries to use all options to reduce prices 
for vaccines, diagnostics and drugs for preventing and 
treating HIV, viral hepatitis and other STIs (and COVID-19).
Strengths
Proven prevention, diagnostic and treatment tools and 
methods exist for all three epidemics, and a growing 
number of countries are using them effectively. Strategic 
information systems are improving, and differentiated 
services are more common.
HIV. Strong testing and treatment programmes exist 
in most countries, with 81% of people living with HIV 
knowing their status, 82% of the people who knew their 
HIV-positive status accessing treatment and 88% of 
the people receiving treatment having suppressed viral 
loads. Strategic information system facilitate fine-tuned 
interventions and accountability, with 63% of countries 
having one integrated information system. Although 
not used widely enough, highly effective prevention 
technologies and interventions exist, and the obstacles 
to their use (such as legal and policy barriers, stigma 
and discrimination and weak demand creation) are well 
understood. Key populations need to be a focus to achieve 
ending AIDS as a public health threat.
Viral hepatitis. Scaled-up vaccination has steeply reduced 
the prevalence of hepatitis B virus infection among children 
younger than five years (to 0.9% in 2019), although birth-
dose coverage has not increased sufficiently. Treatment 
cures exist for hepatitis C virus and are being used 
successfully (notably in Egypt, Georgia, Mongolia and 
Pakistan), and the prices of treatments for hepatitis B 
virus and hepatitis C virus (including generic direct-acting 
antiviral drugs) have fallen steeply in many countries.
STIs. There is a renewed focus on STIs, with 88% of 
countries having STI surveillance in place, progress in 
eliminating the mother-to-child transmission of syphilis, 
64% of countries conducting surveillance of antimicrobial 
resistance and paying more attention to preventing cervical 
cancer. There is a basis for a phased approach that builds 
on existing priority STI interventions and can be expanded 
to other priority STIs.
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Weaknesses
The COVID-19 pandemic caused widespread service 
disruption and highlighted ongoing inequalities and 
inequities in who is able to access, afford and use life-saving 
services and medicines. Diagnostic and treatment gaps 
persist, especially for key populations. Legal and policy 
barriers still pose hindrances, and funding shortfalls are a 
common problem.
HIV. Prevention programmes are not keeping pace, leading 
to growing epidemics, especially among key populations. 
Only 40% of countries have operational needle and syringe 
programmes in the Eastern Mediterranean Region, the 
European Region, the Region of the Americas and parts of 
Asia. Adolescent girls and young women continue to be at 
very high risk of infection in the African Region, and only 55% 
of countries have prevention strategies addressing adolescent 
girls and young women. Widespread use of combination 
prevention interventions is lacking, and funding allocation 
often does not sufficiently reflect epidemic priorities.
Viral hepatitis. Only a fraction of people living with hepatitis 
B virus or hepatitis C virus infection are being diagnosed 
and treated. Globally, only about 5 million people received 
hepatitis C treatment in 2017 and about 4.5 million people 
received hepatitis B treatment in 2016. The new estimates 
bring us to 9.4 million people receiving hepatitis C treatment 
achieving the 2020 targets, but this is still far from our 
goal of 40 million to reach 2030 targets. Although a global 
reporting system was set up in 2018, country reporting is still 
limited and up-to-date data are lacking. Improved strategic 
information is vital to mobilize funding, set priorities and 
monitor and evaluate programmes.
STIs. Major gaps persist in the availability of diagnosis and 
treatment for the four most common curable STIs, although 
88% of countries have STI services as part of primary health 
care. Programmes are generally underfunded, despite 
high levels of STI morbidity and mortality, and data gaps 
undermine advocacy, funding mobilization and scale-up. 
The STAC-HIVHEP urged WHO to advocate for including 
STI programmes in national health budgets and improving 
STI literacy among planners and practitioners in HIV, viral 
hepatitis and other health programmes.
Opportunities
There are opportunities to further integrate or link services 
(such as screening for HIV, viral hepatitis, other STIs, diabetes, 
hypertension etc.), strategic information systems (such as 
with HIV-related systems), laboratory services and platforms. 
But integration approaches should not sacrifice crucial 
features of infection-specific responses (such as community 
engagement and serving key populations). Stronger action 
can be taken to remove social, structural and legal barriers.
Facility-based services and support systems can be made 
more decentralized, people-centred and sustainable through 
the widespread implementation of differentiated service 
delivery models of care such as through pop-up clinics, online 
consultations and teleconsultations, self-testing, multimonth 
dispensing and providing take-home dosages, telemedicine 
for treatment follow-up and retention, contact tracing via 
mobile phone applications and sharing laboratory capacity.
HIV. Reinvigorated primary prevention will strongly influence 
the course of the epidemic. Improved, disaggregated data 
will enable financing, resources and interventions to be 
aligned more effectively with epidemiological trends (and 
use population and location approaches). Community-led 
organizations can be involved more centrally in designing, 
implementing and monitoring services.
Viral hepatitis. Highly effective prevention tools exist for all 
five hepatitis viruses (including a hepatitis B virus vaccine), 
and there is effective treatment for chronic hepatitis B and 
hepatitis C virus infection. There are huge opportunities to 
use comparatively inexpensive hepatitis B virus treatments 
(such as tenofovir) more widely and to achieve further price 
reductions for direct-acting antiviral drugs, especially in low- 
and middle-income countries. Links with noncommunicable 
disease programmes can be extended (for example, with 
cancer control and care or with diabetes screening, as in 
Egypt) and diagnostics can be integrated (for example, via 
multiplex platforms) with HIV, TB and other programmes. 
Simplified testing, care and treatment delivery pathways will 
enhance programmes.
STIs. Cost-effective interventions exist for the major 
infections. Countries need to increase access to and 
manage symptomatic STIs as a priority through appropriate 
approaches. For example, STI screening and treatment of 
key populations with prevention and PrEP programmes 
and giving priority to pregnant women for eliminating 
syphilis are examples of programme integration for STI 
impact. Countries can move from syndromic management 
to etiological diagnosis and management, simplify 
programmes and focus on enhancing access to currently 
available interventions though community testing, lay 
provider testing, assisted partner notification and self-
collection for diagnosis and self-care approaches.
Threats
Funding gaps are expected to continue, especially in the 
wake of the COVID-19 pandemic, and the responses to HIV, 
viral hepatitis and STIs risk being overshadowed by other 
public health and development priorities.
HIV. International donor funding has levelled off over the 
past several years, and the political will to support priority 
services for key and other marginalized populations is 
faltering in several countries.
Viral hepatitis. Programmes are being held back by a lack 
of funding and the high prices of diagnostics, treatments 
and vaccines, especially in low- and middle-income 
countries with a high viral hepatitis burden. The COVID-19 
pandemic threatens the expansion of nascent viral hepatitis 
programmes.
STIs. Programmes are underfunded despite high levels 
of STI morbidity and mortality. Poor awareness about 
the STIs epidemics and continued stigma could lead to 
programmes being eclipsed by other priorities. A resurgence 
of conservatism in many countries threatens STI and sexual 
and reproductive health programmes.
There has been significant progress 
in many areas during this strategy 
implementation period, but most 
global impact targets for 2020 have 
been missed.
There has been solid progress against hepatitis B virus based on 
prevention and increasing immunization rates. The 2020 targets 
for viral hepatitis B prevention are on track, and the global target 
of hepatitis B surface antigen prevalence of below 1% for 2020 
among children younger than five years is one of the first 2020 
targets of the health-related Sustainable Development Goals 
to be met. However, progress in reducing the prevalence of 
hepatitis B infection among children younger than five years is 
not matched with equal progress in addressing hepatitis B and C 
infection among adults. Further, although mortality from hepatitis 
C is declining for the first time, supported by a 10-fold increase 
in treatment for hepatitis C virus compared with the strategy 
baseline, treatment coverage remains 13% (21% diagnosed and 
62% treated) in relation to need. Treatment for hepatitis B is 
progressing much too slowly despite affordable treatments, as 
is hepatitis C prevention and harm reduction among people who 
inject drugs.
The number of people acquiring HIV has not declined sufficiently 
to achieve the Fast-Track commitments to end AIDS by 2030 
as a public health threat. AIDS-related mortality had dropped 
significantly, but an unacceptably high number of people still 
die (42). The response to the major STIs is slowly gathering 
pace after years of neglect, but other than declines in rates of 
congenital syphilis, the rates of other infections have plateaued 
or, in the worst situations, certain STIs may have increased during 




Progress was already insufficient before the COVID-19 pandemic 
further deterred progress in many countries, and a doubling of 
progress was needed to achieve the Sustainable Development 
Goal trajectory. The unprecedented global health crisis has been 
a stark reminder that disease-specific action and universal health 
coverage goals are mutually reinforcing and must be advanced 
together through a people-centred public health approach.
At the end of 2020, the responses to HIV, viral hepatitis and 
STIs were at very different stages of progress, and much can 
be learned across implementation of the strategies to optimize 
opportunities through primary health care as the critical platform 
to ensure universal access to prevention, testing, treatment 
and care over the next decade. Urgent and decisive action is 
necessary now and over the next decade to sustain progress, 
prevent resurgence and accelerate action to eliminate HIV, viral 
hepatitis and STIs by 2030 as part of broader global health goals.
Most 2020 targets have been 
missed. Getting back on track will 
prevent 2 million people from 
dying each year and prevent  
1 million people from becoming 
newly infected each day
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2. Progress towards impact
HIV Impact Service coverage
Rating 2020
Fig. 16. Global trends in people acquiring HIV and people dying from HIV-related causes, 
1990–2019 and projections to 2030
2 500 000
Epidemiological progress
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Source: Avenir Health using 2025 targets and UNAIDS/WHO epidemiological estimates, 2020.
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Fig. 17. Progress towards 90–90–90 and 95–95–95 targets of the HIV service cascade by 
WHO region, 2019
An estimated 1.7 million people newly acquired HIV in 2019, 
the lowest annual number since 1990. HIV incidence rate has 
declined by 30% over the past 10 years. However, progress 
continues to lag substantially behind the global target of less 
than 500 000 people acquiring HIV annually by 2020.
There has been significant progress globally towards the global 
Fast-Track 90–90–90 targets of the HIV testing, treatment and 
viral suppression cascade by 2020. At the end of 2019, 81% of 
people living with HIV knew their HIV status. Of the 38 million 
people living with HIV, 25.4 million, or nearly 67%, were receiving 
antiretroviral therapy; a number that has more than tripled 
since 2010. Close to 59% of people living with HIV globally had 
suppressed viral loads. Further, 85% of pregnant women are 
receiving antiretroviral therapy.
Nevertheless, progress has been uneven, and coverage among 
key populations is low. Children are also not being adequately 
reached, and the world has failed to diagnose and start 
treatment for almost half the children living with HIV. During 
2019, an estimated 150 000 children acquired HIV globally, far 
from the global 2020 target of 20 000. Only 53% of children 
(0–14 years old) were receiving antiretroviral therapy, a total of 
950 000 versus a target of 1.4 million by 2020.
The number of adolescent girls and young women (15-24 years 
old) acquiring HIV declined by 19% globally from 2015 to 2019. 
However, with 280 000 people newly infected in this population 
group, this is still far higher than the target of less than 100 000 
by 2020.
Ongoing expansion of HIV treatment, particularly rapid in 
eastern and southern Africa, has reduced global deaths 
related to HIV to the lowest number since 1994. An estimated 
690 000 people died from HIV-related causes (one third from 
TB) in 2019, a 51% reduction over the past 20 years (20). 
Nevertheless, progress falls short of the global target to 
reduce these to less than 500 000 globally by 2020. Ending 
the global HIV epidemic will require stronger commitment 
to reach the global AIDS strategy 95–95–95 targets by 2030 
by addressing the determinants, inequalities, stigma and 
discrimination that continue to drive the epidemic and prevent 
millions from accessing the services they need. 
95–95–95 target
90–90–90 target
Percentage of people who know their status among people living with HIV
Percentage of people on ART among people living with HIV
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2. Progress towards impact
Fig. 18. New hepatitis B and C infections and mortality, hepatitis B prevalence among children and 
estimated cancer deaths attributable to hepatitis B
























































2015 2020 2025 2030
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Source: International Agency for Research on Cancer and WHO, Global burden of cancer attributable to infections in 2018.
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Global targets aim to reduce the number of people newly 
infected with hepatitis B and C virus by 30% by 2020 and 90% by 
2030. New estimates for 2019 show that 1.5 million people were 
newly infected with chronic hepatitis B infection and 1.5 million 
with chronic hepatitis C infection.
The number of people developing new chronic infections from 
hepatitis B has declined, supported by an increase in the coverage 
of the highly effective hepatitis B vaccine among infants. Globally, 
85% of all infants had received the recommended three doses 
of the hepatitis B vaccine in 2019, up from only 30% in 2000, 
and the global target of the Sustainable Development Goals and 
the global health sector strategy to reduce hepatitis B surface 
antigen prevalence to less than 1% among children younger than 
five years by 2020 has been met. However major gaps remain in 
some regions, including sub-Saharan Africa and South-East Asia. 
The 10-fold scale up of hepatitis C treatment during the strategy 
implementation period has led to a stabilization of mortality for 
the first time, although the annual number of people acquiring 
hepatitis C infection at 1.5 million and dying from this at 290 000 
remain unacceptably high.
Global targets call for a 10% reduction in the numbers of people 
dying from viral hepatitis B and C by 2020 and a 65% reduction 
by 2030. New estimates show that 1.1 million people died from 
viral hepatitis in 2019. A huge scale-up and simplification of 
hepatitis diagnosis and treatment are required to achieve the 
targets for reduced mortality by 2030.
The momentum to address viral hepatitis is growing. Only 17 
countries had national hepatitis strategic plans in 2012, but 
this had increased to 124 by 2019. However, progress in service 
delivery has been insufficient. Only 21% of people living with 
chronic hepatitis C infection know their status. 9.4 million 
people chronically infected with hepatitis C virus were 
cumulatively receiving treatment at the end of 2019, a 10-fold 
increase from 1 million people receiving treatment at the end of 
2015, yet treatment coverage is only 13% of the people in need. 
For hepatitis B, only 10% of people living with chronic hepatitis 
B infection are diagnosed, and 6.6 million (2.2% coverage) are 
receiving treatment.
The availability of effective hepatitis B vaccines, treatment 
for chronic hepatitis B infection and direct-acting antiviral 
treatment cure for chronic hepatitis C infection offer great 
potential for eliminating these diseases as public health 
threats by 2030. A collective effort is needed to address gaps 
in the coverage of testing and treatment of hepatitis B and C 
and in harm-reduction services for people who inject drugs to 
achieve global goals.















Percentage of hepatitis B infected persons diagnosed to end 2019



































Percentage of hepatitis C infected persons diagnosed to end 2019


























32 Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021
2. Progress towards impact
STIs Impact Service coverage
Rating 2020
The global health sector strategy calls for a 90% reduction 
in the incidence of N. gonorrhoeae and T. pallidum (syphilis) 
and elimination of congenital syphilis by 2030. It also calls for 
sustaining 90% national coverage in countries with the HPV 
vaccine in their national immunization programme. This target 
was reinforced in 2020 with a World Health Assembly resolution, 
calling on all countries, by 2030, to achieve 90% HPV vaccination 
coverage, 70% screening coverage and 90% access to treatment 
for cervical pre-cancer and cancer, including access to palliative 
care (43).
The global response is off target. Other than slow declines 
in congenital syphilis, the incidence of most other STIs has 
plateaued (15). Congenital syphilis causes a wide range of 
adverse birth outcomes, including 143 000 early fetal deaths 
and stillbirths, 61 000 neonatal deaths and 41 000 preterm 
or low-birth-weight births in 2016 (15). An estimated 604 000 
women were diagnosed with cervical cancer, causing an 
estimated 341 000 women to die in 2020. These infections 
cause significant morbidity, including adverse birth outcomes 
from vertical transmission, infertility and increased risk of 
transmitting and acquiring HIV.
The global response to STIs is slowly gathering pace after 
years of neglect. A WHO survey in 2019 found that, among 
112 responding countries, 64% of countries had national STI 
strategies and 87% had STI surveillance systems in place – 
although data quality remains weak and most systems do not 
adequately capture the causes of syndromes beyond syphilis. 
About 90% of countries offer HIV and syphilis screening to all 
pregnant women, and 59% had included the HPV vaccine in 
national immunization schedules (41). As of November 2020, 
WHO had validated 15 countries and territories as having 
eliminated the mother-to-child transmission of HIV and/or 
syphilis. Global commitment, funding and an integrated public 
health approach will be essential to bend the curve for these 
infections. Based on improved data in this report and actions 
to strengthen surveillance, more granular and accurate targets 
for viral hepatitis and STIs will be developed as part of the new 
strategies, including interim targets for 2025. 
STIs
Fig. 20. Incidence of gonorrhoea and syphilis: progress towards 2030 targets 
Source: WHO, 2021.
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This chapter accounts for progress achieved in 
delivering the priority interventions and policies 
of the global health sector strategies for HIV, viral 
hepatitis and STIs. It highlights key achievements 
and gaps and recommends priority actions to 
advance progress towards global goals. The analysis 
focuses on disease-specific actions as well as cross-
cutting priorities that can be addressed through 
integrated efforts.
The three global health sector strategies are organized around 
a common synergistic framework of five strategic directions to 
advance progress towards universal access: 
 
 
The sections below describe each of these further.
Information for focused action;
Interventions for impact;
Delivering for equity;
Financing for sustainability; and
Innovation for acceleration.
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Fig. 21. The global health sector strategies for HIV, viral hepatitis and STIs 2016–2021: 
a common universal health coverage framework 
Source: Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. 
Accountability for the global health sector strategies, 2016–2021 (4).
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353. Progress by strategic direction
Granular, person-centred data are a critical 
pillar of primary health care and essential for 
delivering people-centred health services. Data 
are necessary to understand the epidemiological 
context, focus efforts on the right interventions 
and populations, tailor services to meet people’s 
needs and bolster programme improvement. By 
taking an integrated approach to strengthening 
health information systems, countries have 
a major opportunity to strengthen data 
availability and quality across HIV, viral 




By moving beyond 
aggregate measures, 
person-centred data help 
to deliver people-centred 
health services that leave 
no one behind.
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Fig. 22. A district-level data platform of standards and country applications implemented across 
diseases and health
Fig. 23. The Data Initiative with the Global Fund and countries led to improvements in countries with 
fully functioning health management information systems (HMIS) from 22% to 43% and in areas of 
data timeliness and integration, 2018-2019
Source: WHO. Analysis and use of routine health facility data [website]. (44)
Source: Global Fund Strategic performance report, end-2019 (summary). (47)
Applications in country data systems adopted in 40 countries
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Data availability and use are improving. New global and regional 
disease burden estimates are now available for viral hepatitis and 
priority STIs, which will inform future investments. Nevertheless, 
substantial gaps remain in the quality and scope of country-
level surveillance systems for these infections. WHO has also 
supported countries in implementing guidelines for person-
centred data and electronic district-level health information 
systems for HIV and worked closely with the Global Fund to Fight 
AIDS, Tuberculosis and Malaria to promote district-level data use. 
This has helped to accelerate the achievement of key performance 
indicators on health management information system data quality 
from 22% to 43% of countries between 2018 and 2019, and data 
disaggregation exceeds targets. The data summary work is now 
being extended from the aggregate to the individual level and will 
include data modules for STIs and viral hepatitis.
The availability of disaggregated data is also improving, 
especially for HIV. The challenge is to ensure that all data 
have sufficient granularity to explore the gaps in delivery and 
inequalities in reach and are used to leave no one behind.
373. Progress by strategic direction
• Strengthen country-level surveillance capacity for viral 
hepatitis and STIs, with concerted investment in line with 
the recommended 5–10% of programme funds invested 
in strategic information for action.
• Invest in person-centred data and monitoring, especially 
for prevention, to link people at risk to services, retain 
them in services and support them to remain negative.
• Strengthen digital health data capacity, including 
guidance on data interoperability and security.
• Standardize analytical data reviews and build data 
analysis capacity, especially at decentralized levels for 
improving programmes.
• Take an integrated approach to strengthening data 
availability and quality on the populations most severely 
affected and at risk of infection, including population size 
estimates and integrated biobehavioural surveys.
• Joint efforts to strengthen routine data systems and use 
data to improve health services and inform programme 
priorities and design.
• Use data to drive decision-making and ensure that no 
one is left behind, including by strengthening community-
led monitoring that is owned and used by programmes 
working closely with the people who are most 
marginalized and in need to improve access and quality 
and holding service providers and decision-makers 
accountable.
Updated STI global and regional 
estimates for 2020 have been 
developed, and 87% of countries 
report having surveillance systems 
in place, but the scope and quality 
of these surveillance systems 
remain critically weak.
Digital health specifications have 
been initiated for sexual and 
reproductive health and HIV, which 
support electronic reporting and 
are being extended to additional 
health areas. Data security 
and confidentiality need to be 
strengthened.
There have been major advances in 
people-centred monitoring over the 
past five years, with increasing use 
of individual-level data to identify 
gaps and improve services. Patient 
monitoring supports more than five 
million people receiving treatment 
in South Africa and large treatment 
cohorts in many countries. As of 
June 2020, 71% of countries had 
updated their patient monitoring 
systems with WHO person-centred 
monitoring guidelines, and 73% of 
countries used a national unique 
identifier to link patient data.
Electronic district health information 
systems have been strengthened 
through collaboration of HIV, TB, 
malaria and health programmes.
Improved granular generation, review and use of data are improving services using common health information platforms. 
Gaps remain in surveillance systems and facility-level reporting for viral hepatitis and STIs.
Global reporting for viral hepatitis 
has been established, and the 
number of reporting countries has 
increased from 42 in 2018 to 130 
countries in 2019. Updated global 
and regional estimates have been 
developed in collaboration with 
partners, including CDA Foundation, 
Imperial College, the Institute for 
Health Metrics and Evaluation and 
the University of Bristol.
The first global costing of the 
viral hepatitis response has been 
developed showing a need of US$ 
6 billion per year and included in 
the costing for universal health 
coverage.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
Table 4. Information for focused action – global accountability 2020
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Box 5.  
Spotlight: using person-centred 
data to measure people-centred 
services
Person-centred monitoring refers to monitoring that 
places the individual at the centre of health service 
delivery along the cascade of service provision. It involves 
a shift away from measuring services at an aggregate 
level towards supporting individuals as they are tested, 
linked to treatment and retained at various service delivery 
points. Such individual-level monitoring systems help to 
deliver differentiated services, support long-term retention 
in health care, optimize service delivery and improve 
programme outcomes.
In 2017, WHO published new consolidated guidelines 
on person-centred HIV patient monitoring and case 
surveillance (45). A total of 71% of countries have 
updated their patient monitoring systems using these 
guidelines, 73% of countries have national unique 
person identifiers for patient data, and 92% of countries 
have an HIV monitoring and evaluation plan in place. 
The main areas of improvement include updating 
patient monitoring tools to track patients as they move 
across HIV services and facilities; expanding existing 
HIV surveillance systems to adopt or strengthen HIV 
case surveillance; transitioning from paper-based to 
electronic information systems; and investing in human 
resource capacity to analyse and use routine patient 
data to inform programmes. Only 36% of countries have 
systematic processes to monitor antiretroviral drug 
toxicity and 47% to monitor HIV drug resistance.
Each country must determine the pace and pathway 
for developing these systems in accordance with its 
specific context, requirements and the availability of 
human resources, financing and infrastructure capacity. 
When planning for expanding person-centred monitoring, 
countries should analyse the benefits and risks of 
different approaches, in consultation with the affected 
communities. In all cases, person-centred monitoring 
must be based on strict protocols and procedures to 
ensure data security and protect patient confidentiality.
Box 6.  
Extended person-centred data 
for treatment and prevention 
in Zimbabwe
In Zimbabwe, successive population-based surveys 
have shown declines in HIV prevalence larger than 
many other countries in the African Region. In 2020, 
the HIV prevalence among adults over 15 years old 
was 12.9%, down from 18% in 2005. As Zimbabwe 
works towards its national goal of achieving epidemic 
control by 2030, it is expanding data analysis and use 
to understand epidemic dynamics among various 
population subgroups and geographical areas and tailor 
local interventions accordingly.
Since 2017, Zimbabwe has applied WHO guidelines 
to roll out an HIV patient monitoring and case-based 
surveillance system that enables individual-level data 
to be collected and used for improved patient care and 
tracking over the patient’s lifetime (46). Implementation 
began with a pilot phase in two districts during 2017–
2018. Using a combination of electronic and paper-based 
systems, Zimbabwe is able to record sentinel events 
along the cascade, including HIV diagnosis, enrolment in 
care, follow-up, retention and viral load suppression.
An evaluation of the pilot in 2019 showed how weekly 
analysis of data along the service cascade, conducted 
at local levels with the support of community health 
workers, is helping to identify and fill gaps and support 
people living with HIV as they move between facilities. 
The evaluation highlighted several findings that have 
been useful for Zimbabwe as it plans a nationwide roll-
out of the system.
• Most stakeholders felt that the system was cost-
effective since it leveraged existing system capacity 
and operations at the facility level.
• The pilot enabled health facilities to conduct simple 
analysis of clients in their catchment areas and 
helped to improve forecasting of antiretroviral 
medicine requirements and minimize wastage.
• People living with HIV were supported as they moved 
between facilities, allowing improved quality and 
continuity of services.
• The use of unique patient identifiers based on 
antiretroviral therapy was helpful since national IDs 
were not always available, especially for adolescents 
and non-Zimbabweans.
These lessons are also informing the expansion of 
person-centred monitoring to HIV prevention services. 
People received in HIV services who test negative but are 
at risk are referred to prevention services. Person-centred 
monitoring helps to assess whether they are retained in 
these services and to follow up longitudinally to support 
them to remain negative. Efforts are also underway to 
extend the scope of the system, for example to include 
STI data and when possible, data on hepatitis B and C.
393. Progress by strategic direction
The availability and quality of the essential 
packages of health interventions have 
improved significantly for all three disease 
areas, but many gaps remain. Primary 
prevention is lagging behind, especially the 
prevention of HIV and STIs for populations 
most severely affected and at higher risk. 
Available diagnostics and treatment for viral 
hepatitis and STIs are not accessible to many 
people, and investment and political support 
for harm-reduction services are critically 
lacking in many regions. The response to STIs 
has especially lagged behind as a result of 





delivery options need 
to be used optimally to 
expand coverage and 
respond to people’s 
diverse needs and 
preferences.
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Fig. 24. Hepatitis B birth dose vaccination strategies in the national immunization programme, April 2021
Recent evolutions in decentralized, simplified and integrated 
service delivery models, further catalysed by the COVID-19 
pandemic, are showing how existing health system resources 
can be used more effectively to respond to people’s needs and 
preferences. Such people-centred approaches need to be used 
fully to accelerate progress over the next decade. A special 
focus will be needed to recommit to address STIs through 
more effective integration with HIV services and sexual and 
reproductive health services more broadly.
Source: WHO, 2021.
STATUS
HepB-BD introduced to date
HepB-BD only for infants born 
to HBsAG-positive mothers
HepB in childhood schedule 
but no universal HepB-BD
HepB only given to adolescents 
or adult risk groups
No data
Not applicable
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• Reinvigorate primary prevention, including condom use, 
to prevent the sexual transmission of HIV and STIs, with 
a focus on the populations most severely affected and at 
higher risk of infection, and integration with sexual and 
reproductive health services.
• Continue to differentiate and adapt service delivery by 
making it more people-centred to meet the needs of 
different population groups, bringing prevention, testing 
and treatment closer to home and including leveraging 
adaptations from the COVID-19 response.
• Expand, decentralize, integrate and simplify access to 
diagnostics, so that services can be delivered at the 
same site, with the use of affordable and quality rapid 
diagnostic tests, including self-tests, serological and 
molecular point-of-care and near-point of care tests, and 
promote greater task sharing.
• Expand the provision of harm reduction in an integrated 
and comprehensive manner.
• Make use of existing opportunities to accelerate the 
triple elimination of mother-to-child transmission of 
HIV, syphilis and hepatitis B virus through an integrated 
approach that builds on a comprehensive antenatal 
care platform that also incorporates eliminating cervical 
cancer.
• Strengthen the response to antimicrobial drug resistance, 
including through improved use of data to reduce loss to 
follow-up.
• Integrate HIV, viral hepatitis and STI services within 
a broader health systems approach, including with 
noncommunicable diseases and cancer prevention and 
care and primary health care initiatives.
The country-level implementation 
of WHO guidelines has improved 
– 84% of surveyed countries use 
WHO treatment guidelines for 
STIs and 70% provide services or 
links to HIV, reproductive health, 
family planning, and prenatal and 
postnatal services (41).
The HPV vaccine is being rolled out 
– 65 out of 110 countries have now 
added the HPV vaccine into their 
national immunization schedule; 
however, coverage in low-income 
countries is insufficient.
The WHO Model List of Essential 
Medicines has been updated to 
include new treatments for STIs.
There is increasing resistance 
to azithromycin and emerging 
resistance to ceftriaxone, last-line 
treatment for N. gonorrhoeae.
There have been strong gains 
towards achieving the 90–90–90 
targets by 2020 in many countries 
with a high burden of HIV infection, 
but progress varies by region and 
population.
Differentiated approaches to service 
delivery are improving prevention, 
testing and treatment service reach 
and quality.
As of June 2020, 78% of low-
and middle-income countries 
had carried out the transition 
to dolutegravir as first-line 
antiretroviral therapy.
The number of effective options 
for HIV prevention, testing and 
treatment is increasing, including 
the dapivirine vaginal ring as 
an additional prevention choice 
for women; a new dispersible 
strawberry-flavoured formulation 
of dolutegravir for children; and 
diversified testing approaches.
Mother-to-child transmission of HIV and/or syphilis has been eliminated as a public health threat in 15 countries and 
territories. As of June 2020, 82% of countries had a national plan for eliminating the mother-to-child transmission of HIV.
A dual HIV/syphilis rapid diagnostic test has been prequalified by WHO and used as the first test in antenatal care.
Access to infant hepatitis B 
vaccination is high. Coverage of 
three doses of hepatitis B infant 
vaccination reached 85% worldwide, 
although access to a timely birth 
dose remains low in many African 
countries, especially where antenatal 
care coverage is low.
Pangenotypic direct-acting antiviral 
drugs, effective against all six 
genotypes of hepatitis C virus, are 
available, providing an effective cure. 
Coverage of hepatitis C treatment 
has increased 10-fold since 2015 
to 9.4 million people receiving 
treatment; yet overall, only 10% of 
people globally know their hepatitis 
B status, and 21% for hepatitis C and 
even fewer are receiving treatement.
Some champion countries are 
expanding access to hepatitis C 
diagnosis and treatment through 
public health approaches or 
targeting microelimination in the 
most affected subpopulations or 
locations.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
Table 5. Interventions for impact – global accountability 2020
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Box 7.  
Spotlight: applying differentiated service delivery to reach people better
Differentiated service delivery models apply a people-centred approach to simplify and adapt service provision to the 
diverse needs and preferences of beneficiary populations. Since 2016, several countries have implemented various models 
of differentiated service delivery as part of national policy, especially for delivering HIV treatment for adults established on 
antiretroviral therapy, through approaches such as multimonth dispensing of medicines, client-managed groups for drug 
pick-ups and peer support for adherence. Of 120 countries surveyed in 2019, 104 had adopted the WHO recommendation to 
reduce the frequency of clinic visits and antiretroviral medicine refills for people established on treatment (48).
Fig. 25. Policy adoption of differentiated service delivery for HIV, 2020
Such differentiated models have been shown to improve 
individual service uptake and outcomes, enhance service 
quality and reduce unnecessary burden on a health system. 
A rapid systematic review found that HIV treatment retention 
in differentiated service delivery models exceeded 80% 
and was similar to or better than conventional care (49). 
Another review found that differentiated service delivery 
of HIV treatment to people established on treatment saved 
substantial money on travel costs and greatly reduced the 
time required to receive treatment and modestly reduced 
the use of health system resources (50). Differentiated 
approaches are also being increasingly applied across the 
cascade of services for HIV, including prevention, testing, 
linkage to care, antiretroviral therapy and follow-up and 
addressing HIV-related coinfections and comorbidities.
During the COVID-19 pandemic, many countries accelerated 
and successfully applied the principles of differentiated 
service delivery to ensure continued provision of essential 
services to populations in need. For example, many 
countries expanded the use of multimonth dispensing of 
antiretroviral medicines for durations of 3–6 months to 
reduce unnecessary contact with health facilities. Countries 
also used community-based approaches to provide take-
home doses of opioid substitution therapy and PrEP, expand 
the use of HIV self-testing and use telehealth services for 
peer support and care.
Although differentiated service delivery approaches have 
mostly been applied to delivering long-term access to care 
for people living with HIV, their basic principles – simplifying 
and adapting services to the needs and preferences of 
different groups – can also be applied to people with viral 
hepatitis and STIs. For example, people with hepatitis C virus 
infection can be broadly categorized into three groups – 
those who are clinically well and stable, those with advanced 
liver disease requiring more intensive clinical support and 
those requiring additional psychosocial and mental health 
support. Differentiated care models using facility-based, 
community-based or mobile or outreach services can be 
applied to tailor services to their specific needs. Making 
full use of such differentiated approaches will be key to 







Source: HIV Policy Lab, 2021.
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Box 8.  
Differentiated service delivery during COVID-19 in Nigeria
When Nigeria introduced lockdown measures in early 
2020 in response to the COVID-19 pandemic, it was able to 
rapidly address disruptions in HIV treatment by leveraging 
existing policies related to differentiated service delivery. In 
2019, Nigeria had approved a national policy that enabled 
multimonth dispensing of HIV medicines and using 
community-based approaches to tailor and deliver services 
to various groups of people living with HIV. The policy was 
already in place in the 36 states and the Federal Capital 
Territory; however, the benefit of such approaches became 
more noticeable during the pandemic.
Faced with restrictions related to COVID-19, Nigeria was 
able to improve communication and mobilize additional 
community volunteers to deliver medicines to people’s 
homes, especially in hard-to-reach semi-urban and rural 
areas, and to provide adequate supplies to people that 
would cover their needs for months. Services were provided 
in partnership with community-based organizations, 
including the Network of People Living with HIV/AIDS in 
Nigeria. WHO supported the federal government through 
the National AIDS and STIs Control Programme to ensure 
the smooth functioning of differentiated service delivery 
during the lockdown period. WHO also helped to develop 
and disseminate guidance on the continuity of essential HIV 
services in the context of a pandemic.
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The most marginalized, vulnerable and 
underserved populations, who face the 
highest rates of infection, often have the 
poorest access to services. Persistent stigma, 
inequalities, criminalization, violence and 
other sociostructural barriers are preventing 
response efforts from reaching the people and 




To achieve impact, the 
most vulnerable and 
marginalized people 
must be guaranteed their 
right to health.
46 Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021
Fig. 26. Percentage of countries with operating harm-reduction programmes, 2019
Source: Global AIDS Monitoring (UNAIDS/WHO/UNICEF), 2020.
In addition, there are major gaps in reaching adolescent girls 
and young women (15-24 years old) and children. With 280 000 
adolescent girls and young women newly infected each year, this 
is still far higher than the target of less than 100 000 by 2020. 
Only 53% of children (0–14 years old) were receiving antiretroviral 
therapy, a total of 950 000 versus a target of 1.4 million by 2020.
The gaps are most acute for key populations, such as men 
who have sex with men, people who inject drugs, sex workers, 
transgender people and people in prisons. Globally, these people 
and their partners comprise an estimated 62% of the people 
acquiring HIV and they have the highest risk of infection and 
onward transmission in all regions. Some of these populations are 
also disproportionately affected by viral hepatitis. More than half 
the people who inject drugs have had hepatitis C virus infection 
at some point in their lifetime. Modelled projections suggest 
that eliminating the increased risk of hepatitis C transmission 
among people who inject drugs would prevent about 40% of new 
hepatitis C infections from 2018 to 2030 (51). Key populations 
often have coinfections with STIs and viral hepatitis.
A rights-based and people-centred response, planned and 
delivered with leading participation by affected populations, 
will be essential to achieve true universal health coverage.
Yes
No
No, but needles and syringes can be purchased 
legally in pharmacies without a prescription
Needle and syringe





program operational  (n = 134)
64%
36%
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Rates of STI screening among key 
populations are low compared with 
HIV screening and highlight missed 
opportunities to integrate STI 
services with HIV and other health 
services.
• Less than 50% of surveyed 
countries provide STI testing for 
key populations. Further, even 
in countries that report having 
integrated STI services in other 
services such as family planning, 
data are limited on actual STI 
services provided in these 
settings (41).
Services need to be adopted and 
scaled up to reach all partners, 
including through social network 
approaches, based on lessons 
learned from HIV.
Community-led interventions have 
enabled major improvements 
in service coverage for key 
populations; yet gaps remain:
• one third of key populations did 
not know their HIV status (52).
• only 44% of sex workers, 30% of 
gay men and other men who have 
sex with men and 34% of people 
who inject drugs report having 
received at least two prevention 
services in the past three months 
(13).
As of June 2020, 83% of countries 
have a national plan or strategy 
addressing gender-based violence 
or violence against women that 
includes HIV. However, there are 
gaps in access to prevention and 
support against gender-based 
violence for women, gay men and 
other men who have sex with men 
and transgender people.
More work is required across the three strategies to embed 
community-led and community-based efforts across key 
primary health care components, emphasizing integrated 
services, community engagement and inclusive governance 
and policy frameworks.
Adolescent girls and young women face particular 
vulnerability for HIV and STIs related to gender-based 
violence and harmful gender norms – two thirds of 
adolescent girls and young women 15–24 years old in sub-
Saharan Africa do not have comprehensive knowledge about 
HIV (52). As of June 2020, 55% of countries have a national 
prevention strategy to reduce the number of adolescent girls 
and young women and their male partners acquiring HIV in 
communities with high HIV incidence.
Harm reduction coverage for people who inject drugs 
remains low – 40% of countries report having operational 
needle and syringe programmes, and 64% of countries 
reported having operational opioid substitution therapy 
programmes as of mid-2020.
There has been progress in decriminalizing behaviour such 
as drug use, sex work and same-sex relations in some 
countries, but several countries continue to have laws, 
regulations or policies that are barriers to effective service. 
There are major gaps in hepatitis 
B and C testing and treatment in 
all populations, specifically among 
economically disadvantaged 
regions, rural and displaced 
populations and key populations.
Community awareness and 
advocacy related to viral hepatitis, 
including eliminating hepatitis C 
virus among people who inject 
drugs, is increasing; however, 
access to services remains low.
There have been major price 
reductions in hepatitis diagnostics 
and treatment (53) and yet many 
middle-income countries are unable 
to benefit from these prices as a 
result of patent-related barriers.
HIV Viral hepatitis Sexually transmitted infections
• Design and deliver services that are people-centred and 
decentralized in accordance with WHO’s operational 
framework for primary health care (54), leveraging the 
experience of HIV programmes and extending them 
to a wider group of economically disadvantaged and 
vulnerable populations; and engaging communities.
• Strengthen the focus on young people, including young 
people from key populations. 
• Expand the provision of prevention, harm reduction, 
testing and treatment of HIV, viral hepatitis and STIs in an 
integrated and comprehensive manner.
• Address stigma and discrimination, including within 
health-care settings and by focusing on the health-care 
workforce.
• Decriminalize behaviour such as drug use, sex work, 




Table 6. Delivering for equity – global accountability 2020
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Box 9.  
Spotlight: reforming policies and laws
Many of the populations who are most severely affected by HIV, viral hepatitis and STIs are also those that face the greatest 
challenges in accessing necessary services. Gay men and other men who have sex with men, people in prisons and other 
closed settings, people who inject drugs, sex workers and transgender people are confronted with social and structural 
barriers that affect their health, safety and access to services. Their marginalization in turn influences epidemic dynamics 
and diminishes the effectiveness of the response.
Repressive laws and policies are among the major threats to an effective response. More than 100 countries criminalize 
some or all aspects of sex work, and at least 76 countries criminalize sexual relations between people of the same sex. Some 
countries impose the death penalty for convictions under such laws (55). Several countries have adopted more punitive drug 
strategies in 2020 compared with previous years (55).
Fig. 27 Percentage of countries with legal protection for sex workers, 2020
Criminalization directly affects the health and safety of 
these populations. A review of multiple studies found that 
repressive policing practices of sex workers were associated 
with increased risk of sexual or physical violence from 
clients or other partners; and sex workers who had been 
exposed to repressive policing practices had increased risk 
of infection with HIV and STIs (56). In sub-Saharan Africa, 
criminalization of same-sex sexual activity was consistently 
associated with an increased risk of acquiring HIV among 
gay men and other men who have sex with men. The HIV 
prevalence among sampled gay men and other men who 
have sex with men was as high as 52% in countries with 
severe criminalization compared with 8% in countries with 
no criminalization (57). Several countries have taken recent 
steps to review and reform punitive laws and practices, 
supported by advocacy and engagement by communities. 
These efforts must be sustained, and all countries should 
work towards decriminalizing behaviour such as drug use 
and possession for personal use, sex work, same-sex sexual 
relationships and sexual orientation and nonconforming 
gender identities. They must strive to eliminate the unjust 
application of civil law and regulations against people who 
practice these types of behaviour to create equitable and 
enabling environments for an effective public health response.
These approaches are relevant across HIV, viral hepatitis and 
STIs, especially in relation to common determinants for sexual 
behaviour for HIV and STIs and the role of unsafe injection 
behaviour for HIV and viral hepatitis. The key and vulnerable 
populations may vary but the interventions are synergistic.
Constitutional prohibition of
discrimination based on occupation
16%
Constitutional prohibition of
discrimination based on any grounds
13%





Sex work is recognized as work
2%
The total number of reporting countries is 127. 
Source: Global AIDS Monitoring (UNAIDS/WHO/UNICEF), 2020.
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Box 10.  
A western Africa strategy for the health of key populations,  
free from stigma and discrimination
An estimated 5.3 million people are living with HIV in western 
and central Africa, and most of the people acquiring HIV 
are members of key populations and their partners. The HIV 
prevalence in some key populations is as high as 34% versus 
0.3–3.5% in the general population. The syphilis prevalence 
among sex workers is estimated to be about 13% in the 
African Region versus the overall median reported prevalence 
of 3.2% – although data availability is limited.
Conservative cultural and gender norms, pervasive stigma 
and discrimination and legal barriers continue to hinder 
access to health services. Of 25 countries in western and 
central Africa, 16 have laws that criminalize sex work,  
12 criminalize same-sex relations with imprisonment up to 
14 years and 21 retain the death penalty in law for people 
convicted of drug-related offences (58). High levels of 
population mobility, weak health infrastructure and instability 
exacerbate the risks.
Recognizing the social and structural barriers faced by 
key populations in accessing essential services and the 
importance of addressing their needs through an integrated 
public health approach, the Economic Community of West 
Africa States (ECOWAS) adopted a Regional Strategy for HIV, 
TB, Hepatitis B and C and Sexual and Reproductive Health 
and Rights among Key Populations in 2020 (59). 
This strategy for western Africa defines key populations as 
gay men and other men who have sex with men; transgender 
people; people who inject or use drugs; sex workers and 
their clients; and people in prisons and other closed settings. 
It aims to create an enabling legal, social and economic 
environment in ECOWAS for universal health coverage for 
these populations by strengthening national and regional 
leadership and coordination, investing in data systems, 
scaling up comprehensive service packages and ensuring 
the meaningful participation of key populations in design, 
implementation and monitoring. The strategy is guided by 
human rights principles, community empowerment, evidence-
informed interventions and a commitment to accountability.
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More countries are demonstrating domestic 
commitments to finance HIV, viral hepatitis 
and STI services as part of their efforts to 
progress towards universal health coverage. 
Further, major declines in the prices of 
medicines and other health commodities, 
specifically for viral hepatitis and HIV, are 
making a public health scale-up of diagnostics 
and treatment more affordable. For a 
sustainable response, global efforts at disease-
specific resource mobilization must continue 
to be complemented by more integrated 
approaches at country level to mobilize and 
allocate resources efficiently through the 
health system; and ensure that everyone can 
receive services without incurring financial 
hardship – thus attaining universal health 
coverage as delivered through a primary care 
framework. However, the macroeconomic 
and fiscal implications of COVID-19 and the 
response to it will affect domestic as well 
as donor resources in the coming years, 
increasing the challenge everywhere but 





planning and removing 
price and regulatory 
barriers will improve 
access and efficiency.
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Fig 28. Trends in drug prices for a) Lowest prices of direct-acting antiviral drugs 
per 28-day supply b) ARV drug prices
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Sources: a. Accelerating access to hepatitis C diagnostics and treatment: overcoming 
barriers in low- and middle-income countries. Global progress report 2020 (53).  
b. WHO Global Price Reporting Mechanism 2021.
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• Maximize the use of available resources by using data to 
focus resources on the populations and geographies with 
greatest burden and lowest coverage.
• Continue to advocate for including medicines and 
diagnostics for HIV, viral hepatitis and STIs within the 
scope of publicly funded and guaranteed services as part 
of government’s commitment to make progress towards 
universal health coverage.
• Leverage task sharing as a pragmatic response 
to address health worker shortages and expand 
decentralized provision of testing, care and treatment, 
especially for the hepatitis B and C response, to lower-
level health facilities and using existing non-specialist 
and primary health care workforce.
• Leverage efficiency in procurement and supply chain 
mechanisms, including through improved joint analytics 
and data sharing between patient and logistics data 
systems.
• Leverage existing international financing opportunities 
through partners such as the Global Fund and continue 
to strengthen investment cases.
Large funding gaps and global neglect 
of STI funding for many years. 
Some progress in leveraging STI 
management as part of HIV services 
(such as in the case of PrEP) – but 
overall limited success in leveraging 
the increased funding for STIs as 
part of HIV funding.
A low-cost rapid point-of-care test for 
STIs is needed, including tests that 
can diagnose multidrug-resistant 
gonorrhoea and other resistant STIs.
Substantial international funding, 
but new commitments are declining 
and the funding gap is increasing.
The number of new HIV infections 
needs to be reduced rapidly to 
make the long-term costs of care 
sustainable.
Resource needs and cost–
effectiveness data are available. 
The first global costing of the 
viral hepatitis response has been 
developed, showing a need of US$ 
6 billion per year and included in 
costing for universal health coverage; 
however domestic and international 
investments are lagging behind.
In the absence of a donor fund for 
viral hepatitis, many countries that 
have established a national viral 
hepatitis programme have leveraged 
domestic resources in the form of 
either direct government budgetary 
allocations to national programs or 
via reimbursement through national 
health insurance schemes.
There have been major declines in 
drug prices for hepatitis C, expanding 
access significantly.
Reductions in the prices of 
diagnostics and simplification 
of approaches provide major 
opportunities for increased efficiency 
in expanding testing.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
Table 7. Financing for sustainability – global accountability 2020
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Box 11.  
Spotlight: giving priority to eliminating viral hepatitis as part of 
universal health coverage and primary health care
In 2019, WHO and partners developed the first comprehensive 
global resource needs estimates for the hepatitis response 
in the context of universal health coverage. The study found 
that investing an additional US$ 58.7 billion over the period of 
2016-2030, would avert 4.5 million premature deaths by 2030 
and eliminate viral hepatitis as a public health threat in 67 low- 
and middle-income countries that account for the majority of 
hepatitis B and C virus infections (60).
The rapid declines in the prices of commodities, supported 
by increased competition from generic products, are making 
this investment feasible for more countries. Low- and 
middle-income countries can now aim to achieve a price as 
low as US$ 60 per person for a 12-week course of hepatitis 
C treatment with WHO-prequalified generic sofosbuvir and 
daclatasvir (53). Countries have obtained similar reductions 
in prices for hepatitis B commodities. For example, in China, 
the cost for using tenofovir disoproxil fumarate to treat HIV 
was US$ 240 per year through national procurement, whereas 
the cost of tenofovir disoproxil fumarate from the originator 
company to treat people with hepatitis B virus was US$ 2950 
per year, mostly out of pocket. With the expiry of the global 
patent for tenofovir disoproxil fumarate, central negotiations 
and alignment with HIV pricing led to a reduction in the price 
of tenofovir to US$ 30–35 per year by 2019 (61).
An increasing number of champion countries are giving 
priority to financing and delivering viral hepatitis interventions 
as part of national universal health coverage frameworks. 
Supported by government commitment, updated national 
strategic plans and simplified guidelines, countries are 
making hepatitis treatment more widely available by 
implementing a wide range of access strategies. Approaches 
include expanding generic competition, addressing patent-
related barriers, conducting central price negotiations and 
pooled procurement and ensuring timely product registration 
and quality assurance processes.
However, many countries are not benefitting from these 
prices, and great variation in prices and patent barriers 
continue to persist among countries. In particular, high 
prices in upper-middle-income countries because of patents 
remain a major barrier to scale-up. For example, in 2019, 
the lowest generic price for sofosbuvir was US$ 15 per 28-
day supply in India for a WHO-prequalified product. In the 
Russian Federation, which is not included in the voluntary 
licensing agreement with the originator company, the price 
of sofosbuvir was US$ 1099 per 28-day supply. Expanding 
access to simple, affordable and quality-assured hepatitis 
C diagnostics is also urgently needed so that countries can 
screen large numbers of people, identify people who need 
treatment and provide appropriate care.
Continuing to pursue various strategies to reduce prices 
will be essential to make hepatitis services more widely 
available to everyone in need. Further, investing in scaling up 
hepatitis diagnostics and treatment will also bring longer-
term returns and remove an avoidable strain on the health 
system. A hepatitis C virus transmission modelling exercise in 
Pakistan projected that the health system would recover the 
investment in elimination through savings in health-care costs 
from prevented cases of cirrhosis and liver cancer in less than 
three years (62).
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Box 12.  
Domestic financing for hepatitis C treatment  
in the Western Pacific Region
Of the 354 million people living with hepatitis B or hepatitis C virus globally, 35% live in the WHO Western Pacific Region. The 
Region also accounts for 50% of the world’s new cases of liver cancer and associated deaths. Several countries in the region 
are now including the costs of hepatitis commodities in government financing and/or national health insurance coverage.
Table 8. Hepatitis treatment financing in the WHO Western Pacific Region, November 2020
Donor 
supported
Pacific countries: hepatitis B treatment supported by a donor with transition to government financing: 
Fiji, Kiribati, Solomon Islands, Tonga and Vanuatu.
Country Hepatitis B Hepatitis C, direct-acting drugs
Australia Financed Financed
Brunei Darussalam Financed Financeda
Cambodia Out of pocket Out of pocket
China Financed Financedb
China, Hong Kong SAR Financed Financed
China, Macao SAR Financed Financed
Japan Financed Financed
Lao People’s Democratic Republic Out of pocket Out of pocket
Malaysia Financed Financed
Mongolia Financed Financed
New Zealand Financed Financed
Papua New Guinea Out of pocket Out of pocketc
Philippines d Out of pocketd
Republic of Korea Financed Financed
Singapore Financed Financed
Viet Nam Financed Financed
2014 2018 2020
Countries with hepatitis drugs financed 6(all high income) 13 19(including countries with pilots)
aBrunei: using PEG-INF. Direct-acting drugs planned to be used.
bChina: direct-acting drugs under health reimbursements from January 2020.
cPapua New Guinea: pilot employer private-public partnership model, Oro province.
dPhilippines: pilots for hepatitis B and C testing and treatment started with government financing in 2018, with hepatitis B 
national expansion in April 2020.
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Innovations with cross-cutting relevance 
can catalyse the overcoming of barriers and 
move the response to HIV, viral hepatitis and 
STIs closer to the strategy targets. Ongoing 
research in basic science, new tools and 
technologies and service delivery approaches 
is critical to enhance the efficiency, quality 
and impact of the response. In addition, 
innovative methods are needed to tackle 
social and structural determinants related 
to the three disease areas to ensure that 
prevention efforts do not stall. Wider 
diffusion of innovation is necessary to bring 





The potential of 
innovative approaches 
must be fully leveraged 
and brought to scale 
to achieve wider public 
health impact
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Fig. 29. Implementation of HIV self-testing by WHO region, 2020
Sources: Global AIDS Monitoring (UNAIDS/WHO/UNICEF) and WHO, 2020.
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Table 9. Innovation for acceleration – global accountability 2020
• Leverage the potential of innovative service delivery 
approaches, including through self-management and 
care approaches and community-led delivery, building on 
lessons learned from the COVID-19 response.
• Leverage the potential of digital tools, including for 
demand creation, service delivery and monitoring and 
evaluation.
• Ensure continued investment in research in priority areas 
– such as vaccines for HIV, hepatitis C virus, gonorrhoea 
and HSV and a functional cure for hepatitis B.
• Seek opportunities for innovative approaches to address 
the social determinants of health.
Expanded use of self-management 
approaches such as self-sampling 
for STIs.
Various new products in progress: 
• Prequalification of diagnostic 
tests for N. gonorrhoea and rapid 
syphilis testing.
• New treatments for gonorrhoea 
to address antimicrobial 
resistance.
• Alternative treatments for 
maternal syphilis.
• Promising vaccines against 
gonorrhoea.
Innovation in service delivery 
models is needed to integrate STI 
testing into existing diagnostic 
platforms and the provision of 
integrated services.
Innovation is needed to address 
social and structural determinants 
relevant for preventing STIs and HIV.
The HIV response has strongly 
focused on innovation in 
technologies and service delivery 
models.
Increasing options for HIV 
prevention and treatment, including 
the dapivirine vaginal ring as an 
additional prevention choice for 
women and a new dispersible 
strawberry-flavoured formulation of 
dolutegravir for children.
Other innovations are in the pipeline 
– related to long-lasting treatment, 
prevention technologies and the 
use of person-centred data, unique 
identifiers to support people as they 
move between facilities and digital 
health tools to improve utilization of 
appointments and services.
HIV mRNA vaccines are once again 
showing promise, in part because 
of extensive research to develop 
vaccines for COVID-19.
Progressive simplification in 
diagnostics and treatment 
algorithms and service delivery 
models for hepatitis C virus.
Progress in obtaining a cure for 
hepatitis B is required to achieve the 
2030 strategy targets.
Implementation innovations to 
simplify diagnostics and their 
delivery and access are needed 
as part of primary health care 
approaches. Innovation needs 
further development and quality 
products including core antigen 
for hepatitis C virus as a rapid 
diagnostic test but even simply 
having high-quality hepatitis B 
surface antigen tests.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
Strong focus on cross-cutting innovations, such as differentiated and community-led models – accelerated during COVID-19.
Availability of new technologies to scale up diagnostics, such as triple HIV, syphilis and hepatitis B tests; point-of-care nucleic 
acid tests for hepatitis B and C virus; and self-testing for hepatitis B, hepatitis C and STIs.
Greater use of virtual platforms and digital tools, especially to reach young people.
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Box 13.  
Spotlight: advancing community engagement and community-led 
service delivery
In response to the COVID-19 pandemic, community-based 
organizations worldwide stepped up efforts to identify and 
expand innovative ways to continue to reach people with 
essential services in contexts of lockdowns and stay-home 
measures, physical distancing requirements, difficulties in 
accessing health-care services and supply disruptions. As 
highlighted in section 1.2, community-based organizations 
delivered essential supplies such as antiretroviral therapy 
and harm-reduction services directly within communities 
and to people’s homes, expanded the use of self-testing 
and self-management approaches and used telehealth 
and social media to provide information and support, often 
integrating COVID-19 messaging in their work.
Several of these approaches were already being successfully 
used before the COVID-19 pandemic. Their expanded use in 
the context of a public health crisis has clearly demonstrated 
how community engagement plays a major role in delivering 
people-centred services to populations that are hard to 
reach. Community-based and peer-led approaches bring 
services closer to people in need and deliver them in an 
environment of trust. They empower individuals with a wider 
choice of interventions, including greater possibilities for 
self-care and autonomy. They also empower communities 
to play a lead role in advocacy, priority-setting and designing 
services to meet their needs and promote accountability.
Community-led service delivery is integral to effective 
primary health care and an essential complement to 
facility-based services. The health sector is transforming 
rapidly with an increasing number of new diagnostics, 
devices, medicines and other technologies that can be 
self-administered and self-managed, often supported by 
digital innovations. Community-based organizations and 
community workers support the delivery of these new 
technologies as a means to expand primary health care 
beyond traditional delivery models and enable more people 
to realize their right to health.
Young people in particular have emerged as critical 
gatekeepers in pioneering and sustaining community-
led innovations and should be further supported in 
consolidating their leadership into the next phase of work 
to reset the responses to HIV, hepatitis and STIs back on 
track. In Manipur, India, young people are working with 
mental health professionals to provide psychosocial support 
and information for young transgender people during 
the pandemic. In Zimbabwe, community adolescent HIV 
treatment supporters provided information, referrals and 
support to their peers using mobile phones (63).
The innovations introduced during the COVID-19 pandemic 
must be sustained and leveraged to reach larger numbers 
of the people most severely affected and at higher risk – to 
achieve the goals of eliminating HIV, viral hepatitis and other 
STIs as public health threats by 2030. Community-led and 
community-based responses require greater investment 
with stronger links to primary health care and its focus on 
building people-centred, resilient and sustainable health 
systems that uphold the right to health, promote social 
justice, empower individuals and communities and address 
the determinants of health. Countries are encouraged to 
further scale up innovative community-led approaches 
as they strive towards elimination, in accordance with 
the pathways described in the WHO/UNICEF operational 
framework for primary health care (54).
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Box 14.  
Exploring the potential of digital 
health to reach young people in 
South Africa
Young people in southern Africa have a high prevalence 
of STIs but poor knowledge of STIs and of available 
prevention and health-care services. Young people also 
report concerns around confidentiality, provider attitudes 
and feelings of stigma and shame as barriers to accessing 
services (64).
Faced with COVID-19, a project providing sexual and 
reproductive health services to adolescent girls and young 
women 15–24 years old in South Africa rapidly adapted 
its service delivery to the COVID-19 context (65). By using 
social media, chatbots and messaging apps, the project 
ensured that young people continued to have access to 
information and education materials in times of lockdown. 
The project decentralized service delivery to mobile 
clinics and community delivery points and expanded 
the use of telehealth for screening, consultations 
and psychosocial support. They also sent electronic 
prescriptions and postal self-testing or self-sampling kits 
for HIV, chlamydia, syphilis and gonorrhoea, with follow-up 
through telemedicine.
The project found that young clients responded positively 
to having a wider choice of service delivery options for 
sample collection, diagnosis, receiving results, initiating 
treatment and notifying partners. It also found high 
utilization of social media for information, screening and 
follow-up, demonstrating the potential to extend these 
adaptations in the future.
Box 15.  
Self-sampling for STIs to 
maintain services for key 
populations in Thailand
Thailand faces a high burden of STIs among gay men and 
other men who have sex with men and among transgender 
women. In the first half of 2019, the COVID-19 pandemic 
resulted in a decline of 50–75% in clients testing for HIV 
and STIs in major HIV and STI service delivery centres.
To maintain access to sexual health services while 
respecting physical distancing and occupational safety 
regulations, Thailand’s key population–led health services 
programme introduced self-sampling for STIs at major 
key population-led health clinics for the first time. Uptake 
of self-sampling was high, and the rate of acceptance of 
STI self-sampling increased from 48% in May 2020 to 78% 
by July 2020. Thailand also adapted other services to the 
COVID-19 context, such as extending PrEP prescriptions 
from three to six months for continuing clients, delivering 
medication and supplies discretely and using telehealth 
consultations.
Such adaptations provide greater accessibility and 
acceptability of services for populations in need and can 
be sustainable over the long-term. A meta-analysis of 
data from 11 studies from different countries found that 
self-collection of samples nearly tripled the overall uptake 
of STI testing services compared with clinician-based 
collection, offering an important additional strategy to 
increase service uptake (66).
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Joint action can create synergy across 
health and community systems to 
ensure the widest possible access 
to high-quality services for all 
populations in need and advance the 
goals of universal health coverage. 
This section accounts for the status 
of cross-cutting priorities that were 
identified in the mid-term review in 
2018, identifies additional priorities 
by drawing on lessons from the 
COVID-19 response and provides a 
view forward to 2030.
3.6 Cross-cutting actions
The public health 
response to HIV, viral 
hepatitis and STIs offers 
many opportunities to 
join forces to accelerate 
towards achieving the 
2030 elimination targets.
Priorities Status in 2020 Catch-up actions to 2030
Actions identified in the mid-term review (2019)
1. Leverage common 
disaggregated data 
platforms
Electronic district-level data systems have been 
implemented in most countries, with regular 
data review to improve programmes. However, 
gaps remain in facility-level reporting for viral 
hepatitis and STIs and in the security and 
interoperability of data systems.
• Strengthen digital health data, including guidance on data 
interoperability, security and unique identifiers.
• Conduct standardized analytical reviews and build 
capacity to use data at decentralized levels to improve 
programmes.
• Consider agile, small-scale surveys across the three 
disease areas that can assess trends and progress in 
specific populations.
2. Scale up point-
of-care diagnostics 
and self-testing
The availability of diagnostics for HIV, viral 
hepatitis and STIs is improving, supported by 
recent innovations. However, there are many 
missed opportunities to leverage common 
platforms for service delivery and common 
learnings, such as in the case of self-testing 
across all three disease areas. 
• Make self-testing available for all three disease areas, 
especially to reach key and vulnerable populations and men.
• Strengthen joint diagnostic platforms that can be 
leveraged across all three disease areas and more widely 
across health.
3. Achieve triple 
elimination of 
mother-to-child 
transmission of HIV, 
hepatitis B virus and 
syphilis and explore 
extending the 
elimination focus to 
children
There has been major progress in aligning 
guidelines and processes and validating the first 
set of countries for dual and triple elimination. 
Fifteen countries have already been validated 
as having eliminated the mother-to-child 
transmission of HIV and/or syphilis as public 
health threats, and two additional countries are 
preparing to submit country data to join the path 
towards elimination. Stronger incentives to align 
countries in the full path towards elimination 
would strengthen the approach, together with 
further inclusion of hepatitis B.
• Strengthen approaches and incentives to involve 
countries in the full path towards elimination, including in 
larger countries with a higher burden of disease.
• Scale up the triple elimination of mother-to-child 
transmission and, where feasible, expand approaches to 
validate adult elimination, such as for hepatitis C virus 
infection.
• Develop strategies to expand the focus on eliminating 
vertical transmission to eliminating infections among 
children across the diseases.
Table 10. Cross-cutting priority actions for the next decade
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Priorities Status in 2020 Catch-up actions to 2030
4. Improve access 
to drugs and 
diagnostics
The price reductions have been remarkable 
for hepatitis C medicines in the past three 
years and HIV over the last two decades. 
These need to be extended and efforts made 
to include the costs of expanding coverage of 
these within national health plans, including 
any health insurance entities, and to provide 
the needed financing across all three disease 
areas as part of universal health coverage. In 
addition, developing an end-to-end process for 
antiretroviral medicines for children, early infant 
diagnosis and using multi-disease platforms can 
improve the effectiveness of interventions.
• Include drug and diagnostics costs increasingly in country 
health financing, for example as for HIV and viral hepatitis 
in Rwanda’s health insurance program and for hepatitis B 
in China’s insurance programs. This also enables further 
reductions as prices are aligned, for example between 
hepatitis B virus and HIV.
• Promote South-to-South support, for example Egypt’s 
support for eliminating hepatitis C more widely in Africa.
• Strengthen subnational use of unique identifiers to better 
match patient numbers with drug and diagnostic stocks.
• Facilitate drug development for new gonorrhoea 
treatment and options for syphilis treatment and 
availability of STI drugs and diagnostics at the primary 
health care level.
5. Protect against 
the threat of 
antimicrobial 
resistance
There have been strong improvements in 
HIV medicines with regards to antimicrobial 
resistance supported by a global action plan. 
Cross-cutting antimicrobial resistance actions 
across HIV, STIs and TB could be strengthened.
• Improve surveillance and monitoring of antimicrobial 
resistance for HIV and STIs.
• Improve data use to reduce loss to follow-up on life-long 
HIV treatment.
• Align actions to address antimicrobial resistance for HIV 
and STIs and coordinate with cross-cutting management 
of antimicrobial resistance.
6. Strengthen 
joint responses to 
HIV, viral hepatitis 
and STIs with 
TB and other key 
comorbidities
There has been major progress in provision of 
testing and treatment, but TB remains the major 
cause of death among people living with HIV. 
Programmes in many countries in sub-Saharan 
Africa remain separate in terms of management, 
supply chains and monitoring.
• Review integration of HIV and TB programmes, especially 
in sub-Saharan Africa, while continuing strong progress in 
aligning testing and treatment.
• Align joint monitoring approaches in terms of use of 
health information system platforms such as DHIS-2, 
programme reviews and ongoing data use to improve 
services.
7. Integrate sexual 
and reproductive 
health and rights
Many countries have pioneered important 
approaches in relation to key and vulnerable 
populations, but progress has met significant 
barriers. Renewed efforts are required to secure 
sexual and reproductive rights for all.
• Extend activities across all three disease areas and 
mainstream key components in universal health care 
approaches, where the tracer is often progress in key and 
vulnerable populations.
• Integrate STI prevention and care services into HIV, 
adolescent health, antenatal care and sexual and 
reproductive health services and primary health care.
• Further integrate sexual and reproductive health rights 
including STIs into existing programmes, including those 
supported by the Global Fund and the United States 
President’s Emergency Plan for AIDS Relief (PEPFAR).
8. Address social 
and structural 
determinants
The failure to achieve HIV incidence reduction 
targets and STI targets highlights the need 
to address social, behavioural and structural 
determinants more directly in the next decade to 
progress towards elimination.
• Support national prevention programmes with strong 
leadership to tackle social and structural determinants, 
since many countries suggest these have not been 
adequately supported at the highest level
• Develop activities across the Triple Billion targets, 
leveraging the increasing WHO emphasis on social and 
structural determinants.
Actions identified to leverage innovations and lessons from the COVID-19 response





Many of the policies have been developed, 
but they gained additional impetus in 
implementation in response to the COVID-19 
pandemic. This momentum needs to be further 
leveraged to build back a stronger response to 
HIV, viral hepatitis and STIs.
• Extend flexibility in policies, such as multimonth 
dispensing of antiretroviral medicines to six months, and 
require differentiated care policies to be in place.
• Strengthen the use of person-centred data and digital 









Community engagement has been a critical 
part of the response, but communities have 
increasingly taken on additional responsibilities 
to integrate prevention, testing and treatment 
with innovative approaches in response to the 
COVID-19 pandemic.
• Integrate community-level services to bring together 
prevention, testing and treatment.
• Develop direct, simplified service delivery that goes 
beyond health facilities, using community networks and 
workplaces to reach the most vulnerable populations, 
adolescent girls and young women and men.
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Box 16.  
Spotlight: accelerating progress within the frameworks of universal 
health coverage and primary health care
The responses to HIV, viral hepatitis and STIs play an 
important role in advancing the global goals of universal 
health coverage and primary health care (67,68). Similarly, 
increased investment in the key components of primary 
health care drive progress towards disease-specific goals 
and people-centred care as critically important elements 
of the push for universal health coverage. With universal 
health coverage as the goal, strengthening primary health 
care while continuing with disease-specific approaches can 
ensure optimal opportunities for people-centred services 
and greater efficiency through strengthened integration. 
More efforts are needed to separate ends and means; 
ensuring that more integrated systems are accountable 
to deliver disease-specific goals, mainly through primary 
health care, to deliver on progress towards universal health 
coverage. This requires greater alignment of disease-
specific and overall health system efforts at the policy, 
programme, and service levels.
Universal health coverage means that all people have 
access to the health services they need, when and where 
they need them, without financial hardship. Effective control 
of disease is therefore integral to progress towards universal 
health coverage. The global health sector strategies for HIV, 
viral hepatitis and STIs recognize universal health coverage 
as an overarching guiding framework and contribute 
towards its progressive realization; in turn, progress towards 
universal health coverage enables a comprehensive 
response to these diseases.
People-centred and resilient health systems that deliver 
primary health care are essential to achieve universal health 
coverage. In the Declaration of Astana (2018), countries and 
international partners committed themselves to orienting 
health systems towards primary health care for accelerated 
progress on universal health coverage and the health-related 
Sustainable Development Goals (67).
Primary health care covers the range of disease prevention, 
health promotion, treatment, rehabilitation and palliation care 
that are needed throughout a person’s lifespan, delivered as 
close as feasible to people’s everyday environment. WHO’s 
vision for primary health care seeks to achieve healthy lives 
and well-being for all by building people-centred, resilient 
and sustainable primary health care–based health systems 
that uphold the right to health, empower individuals and 
communities and address the determinants of health through 
multisectoral policy and action.
The global response to HIV, viral hepatitis and STIs is 
anchored in these principles. Joint efforts across these 
diseases are important steps towards advancing universal 
health coverage and primary health care through disease-
specific action. These include strengthening cross-cutting 
surveillance and information systems, deploying multi-
disease diagnostic technologies, strengthening self-care 
and self-management approaches, addressing common 
price and patent-related barriers, integrating disease-
specific financing into universal health coverage packages, 
empowering communities and addressing common social 
determinants of health.
For many countries, integrating primary health care across a 
wide range of policies, strategies, activities and services is 
likely to require substantial transformation of how health-
related policies and actions across disease areas are given 
priority, funded and implemented (67). Each country will 
progress towards universal health coverage and primary 
health care in accordance with local contexts and priorities. 
Countries will need to assess, set priorities for, optimize 
and sequence their actions as part of national health sector 
planning. These processes should occur in the context of 
an inclusive planning process with community participation 
that includes the most vulnerable, disadvantaged and 
marginalized people, and care must be taken to ensure 
that greater integration does not compromise the focus on 
disease-specific responses that serve these populations.
Fig. 30. Primary health care: a whole-of-society approach
Source: WHO & UNICEF (69).
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Each of the global health sector strategies defines fast-
track actions that WHO must undertake to support 
countries to accelerate progress in the fight against 
HIV, viral hepatitis and STIs. This section highlights 
the WHO actions for which major gaps remain and 
identifies suggested steps to address these gaps.
3.7 WHO actions
Box 17.  
Spotlight: contributing to achieving the WHO Triple Billion targets
WHO’s Triple Billion targets are an ambitious initiative to 
achieve measurable impact on the health of billions of people 
worldwide by 2023 such that:
• one billion more people benefit from universal health 
coverage;
• one billion more people are better protected from health 
emergencies; and
• one billion more people enjoy better health and well-
being.
These targets provide the foundation of WHO’s Thirteenth 
General Programme of Work and are an integral part of WHO’s 
results framework to measure and improve how WHO’s 
affects health at the country level.
Progress towards eliminating HIV, viral hepatitis and STIs 
as public health threats contributes tangible results towards 
achieving the Triple Billion targets.
• The first billion. All three disease strategies share a 
vision to deliver the three dimensions of universal health 
coverage – improving the availability and quality of 
essential health services, ensuring equitable access 
to services in relation to need and reducing costs and 
providing financial protection for those who need the 
services.
• The second billion. With their contributions to building 
health system capacity and resilience, HIV, viral hepatitis 
and STI programmes also contribute to public health 
emergency preparedness, detection and response.
• The third billion. By addressing structural barriers 
and promoting gender-responsive programming, they 
contribute to better health and well-being for all.
 








Reflect key actions in the policy 
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Global health 
sector strategy 
WHO action with significant gap in 
2020
Suggested steps to address the gap by 2030
HIV Advocate for and support the expansion of 
new prevention technologies.
Include new approaches for prevention, including social and 
structural determinants, in the next phase of the global health 
sector strategies with reference to the UNAIDS Global AIDS Strategy 
2016–2026 (70) and its three strategic priorities: maximize equitable 
and equal access to HIV services and solutions; break down barriers 
to achieving HIV outcomes; and fully resource and sustain efficient 
HIV responses and integrate them into systems for health, social 
protection, humanitarian settings and pandemic responses.
Provide guidance on combination HIV 
prevention.
Provide implementation guidance on how to balance funding for 
various prevention priorities.
Viral hepatitis Support countries with tools and technical 
assistance.
Strengthen partner technical support and support from WHO 
regional offices.
Support countries in fully implementing 
WHO’s injection safety policy and global 
campaign.
Highlight injection safety in the next phase of the global health 
sector strategies.
Provide advocacy and technical support to 
countries to mobilize commitment to harm 
reduction.
Address barriers to harm reduction as a cross-cutting priority in the 
next phase of the global health sector strategies.
Provide guidance on quality assurance and 
quality improvement systems.
Assess approaches to improve quality assurance and improvement 
in countries.
Provide policy and technical guidance aimed 
at building a competent workforce.
Develop guidance on differentiated human resources support for 
hepatitis services.
Provide technical support to countries to 
forecast the need for essential hepatitis 
commodities.
Initiate forecasting for hepatitis C commodities in the 2021 
forecasting meeting for drug and diagnostics stakeholders and 
partners.
Support regulatory authorities in pre-
market assessment and registration of new 
hepatitis medicines and diagnostics, with 
post-market surveillance.
Strengthen post market surveillance to support regulatory 
authorities.
Assess the quality and performance of 
commercially available hepatitis diagnostics.
Consider in the next phase of the global health sector strategies.
STIs Ensure linkage of some components of STI 
surveillance to existing mechanisms.
Develop a new monitoring and evaluation and surveillance 
framework for STIs.
Provide technical support to countries with 
STI programmes.
Strengthen joint STI and HIV country support.
Update and disseminate guidance for 
targeted populations on STI vulnerability and 
risk-reduction interventions.
Include stronger focus on key populations in the next phase of the 
global health sector strategies and generate better data.
Strengthen efforts to ensure that high-
quality diagnostics for STIs are accessible 
and available.
Implement STI diagnosis, screening strategies for key population 
and vulnerable populations such as adolescents, pregnant women 
and other bridge populations, including men; and facilitate the 
development of low-cost point-of-care tests for STIs.
Develop and support public–private 
partnerships to catalyse the development of 
new technologies.
Develop and support public–private partnerships to catalyse the 
development of new technologies.
Table 11. WHO action with gaps in 2020 and steps to address these by 2030
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4
Progress by WHO region
4.1 African Region
Table 12. African Region: data at a glance, 2019–2020
Disease area Indicator Numbers
HIV (2019) People acquiring HIV 970 000 
[730 000–1 300 000]




Incident cases of hepatitis B infection 990 000
[660 000–1 600 000]
Incident cases of hepatitis C infection 210 000
[150 000–370 000]
People dying from hepatitis B infection 80 000
[47 000–110 000]
People dying from hepatitis C infection 45 000
[23 000–72 000]
STIs (2020) Incident cases of gonorrhoea 19 200 000
[10 000 000–32 200 000]
Incident cases of syphilis 2 200 000
[1 300 000–3 100 000]
The African Region leads the way 
in HIV testing and treatment 
and has the opportunity over 
the next decade to extend this 
to addressing hepatitis B and C 
and syphilis transmission from 
mother to child
70
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Table 13. African Region: highlights and priority action
Countries in the Region with high 
HIV prevalence also face a high 
prevalence of HPV infection and 
cervical cancer incidence and 
mortality, but many countries have 
not yet introduced HPV vaccination 
for girls, and the integration of 
cervical cancer screening with HIV 
services needs to be strengthened.
There has been progress in dual 
testing for HIV and syphilis and 
approaches for eliminating the 
mother-to-child transmission of 
the two diseases.
Very high levels of STIs and 
HIV incidence among women in 
antenatal care have shown the 
need for stronger approaches to 
integrate prevention and treatment 
and to tackle similar social and 
sexual determinants.
To strengthen STI and HIV 
prevention surveillance, joint 
approaches, including STI 
prevalence surveys, are required.
Data availability and quality have improved 
greatly – all countries are reporting on key 
HIV cascade indicators; HIV programme 
data are integrated into the health 
management information system; and key 
population size estimates are improving. 
Of 47 countries in the region, 44 have size 
estimates for sex workers, 40 for gay men 
and other men who have sex with men, 
20 for people who inject drugs and 7 for 
transgender people.
70% [58–80%] of the people living with 
HIV have access to HIV treatment, and 
five countries (Botswana, Eswatini, 
Namibia, Zambia, and Zimbabwe) have 
achieved the 90–90–90 targets in 2019.
Differentiated service delivery is improving 
uptake and quality – 42 countries 
implementing multimonth dispensing of 
antiretroviral drugs for 3–6 months.
Access to voluntary medical male 
circumcision is expanding – 27 million 
adolescent boys and men in 15 countries 
reached in eastern and southern 
Africa, achieving 60% of the target and 
preventing 340 000 people from acquiring 
HIV by 2019.
PrEP services are scaling up– of 47 
countries in the Region, 22 provide PrEP 
to adolescent girls and young women, 
sex workers, gay men and other men who 
have sex with men, transgender people, 
people who inject drugs and/or prisoners.
Twenty-eight countries had national 
hepatitis strategic plans in 2018.
Access to diagnosis and treatment 
is still limited.
Hepatitis reporting has improved 
significantly in the Region since 
the mid-term report but major gaps 
remain.
Egypt has initiated support for 
planning towards eliminating viral 
hepatitis in sub-Saharan African 
countries, a leading example of 
South-to-South support.
Joint approaches to viral hepatitis 
and HIV coinfection provide 
opportunities, given the reductions 
in prices for hepatitis B and C 
treatment.
HIV Viral hepatitis Sexually transmitted infections
• Invest in integrated data systems and streamline the 
governance of data reviews and use.
• Continue to scale up differentiated service delivery, 
leveraging the innovations from the COVID-19 response.
• Intensify efforts to reach men at higher risk of HIV 
infection.
• Advance integrated people-centred health services 
across diseases, with greater decentralization, task 
sharing and community engagement as part of universal 
health coverage.
• Continue to advocate for domestic investment and 
innovative financing mechanisms; especially to address 
the chronic funding gaps for viral hepatitis and STIs.
PRIORITY  
ACTIONS
Three countries have achieved elimination of mother-to-child transmission of HIV and/or syphilis;  
11 are on the path to elimination.
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Box 18.  
Engaging communities in voluntary medical male circumcision in 
Malawi and the United Republic of Tanzania
Voluntary medical male circumcision is a critical component 
of a combination prevention strategy in settings with 
high HIV prevalence, in particular in eastern and southern 
Africa. Voluntary medical male circumcision is also a 
critical strategy to link adolescent boys and men to health 
services and increase service uptake. Many countries are 
implementing strategies to generate demand and address 
barriers to scaling up voluntary medical male circumcision 
among adolescent boys and men.
In a high-burden district of Malawi, satisfied prior clients 
of voluntary medical male circumcision were engaged as 
community mobilizers to expand demand creation. They 
were provided with a bicycle for transport, identification 
cards and branded T-shirts and equipped with training and 
job aids to address common myths and misconceptions 
regarding voluntary medical male circumcision among men 
in their communities. The uptake of voluntary medical male 
circumcision in the district increased from 32% in 2017 to 
71% in 2018, the highest level in five years (71).
In the United Republic of Tanzania, after data analysis 
revealed that male circumcision rates among men 
25–29 years old were low in priority districts, an initiative 
sought to integrate voluntary medical male circumcision 
within existing community-based mobile HIV testing. 
Adjacent tents offering HIV testing and voluntary medical 
male circumcision were set up near hotspots, and peer 
educators linked the clients of HIV testing to voluntary 
medical male circumcision. The initiative helped to reduce 
waiting times and travel distance and provided more 
privacy compared with facility-based voluntary medical 
male circumcision. Older men represented 38% of voluntary 
medical male circumcision clients reached through mobile 
teams versus 11% of clients reached through facility-based 
modalities (72).
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4. Progress by WHO region
4.2 Region of the Americas
The Region of the Americas has led the 
approaches to dual elimination of mother-to-
child transmission of HIV and syphilis and 
delivering the HIV service cascade for key 
populations. Over the next decade, they will 
need to fill the gaps in the service cascade for 
HIV, viral hepatitis and STIs
Table 14. Region of the Americas: data at a glance, 2019–2020
Disease area Indicator Numbers
HIV (2019) People acquiring HIV 170 000 
[110 000–240 000]




Incident cases of hepatitis B infection 10 000
[5 100–26 000]
Incident cases of hepatitis C infection 67 000
[63 000–73 000]
People dying from hepatitis B infection 15 000
[8 500–23 000]
People dying from hepatitis C infection 31 000
[19 000–84 000]
STIs (2020) Incident cases of gonorrhoea 9 800 000
[5 300 000–17 000 000]
Incident cases of syphilis 2 500 000
[1 500 000–3 500 000]
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Table 15. Region of the Americas: highlights and priority actions
• Expand integrated testing and treatment services, such 
as the joint elimination of mother-to-child transmission 
of HIV and syphilis as part of maternal and child health, 
common platforms for HIV and STI testing and mental 
health.
• Facilitate access to commodities by taking a joint 
approach to addressing market and patent barriers.
• Expand the roll-out of differentiated approaches for HIV, 
including multimonth dispensing of medicines, expanded 
role of lay providers and use of telemedicine.
• Improve surveillance and information systems, especially 
on viral hepatitis and STIs.
• Strengthen surveillance of antimicrobial resistance for 
N. gonorrhoeae and align treatment guidelines with local 
susceptibility patterns.
Key populations have a high 
burden of syphilis, and syphilis is 
increasing among pregnant women 
in some countries. Congenital 
syphilis cases are underdiagnosed 
and underreported.
The number of people acquiring HIV 
declined between 2010 and 2019 
in the Caribbean (29%) but grew in 
Latin America (21%), with the overall 
numbers for the Region stabilizing 
since 2019.
Coverage of HIV treatment services 
is increasing (67%), and most 
countries have adopted “treat all” 
policies.
Coverage of HIV prevention services 
is uneven. About 64% of gay men 
and other men who have sex with 
men reported using a condom at 
last anal sex, but the number is less 
than 50% in nine countries. Roll-out 
of PrEP has been slow.
Nine countries have developed key 
population prevention cascades 
and implemented policy and 
programmatic changes based on 
their findings.
HIV self-testing is expanding, with 
national policies adopted in five 
countries and being developed in 15 
countries.
Previously adopted preventive 
interventions, including vaccination 
and blood safety, have enabled 
the regional elimination of early 
childhood transmission of hepatitis 
B (hepatitis B surface antigen <0.1% 
among children five years-old).
A total of 23 countries had national 
hepatitis strategic plans in 2020 
versus 10 in 2015.
However, access to diagnosis 
and treatment is still limited, and 
few people living with hepatitis B 
and hepatitis C virus have been 
diagnosed.
High prices of commodities and 
complex patent protection schemes 
that limit access to generics 
continue to pose barriers.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
Eight countries have achieved elimination of mother-to-child transmission of HIV and/or syphilis.
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Box 19.  
Community-led solutions to maintain HIV and STI services during the 
COVID-19 pandemic in Argentina and Guatemala
In Argentina, Fundación Huésped provides community-
based services related to HIV and AIDS, viral hepatitis, 
STIs and other sexual and reproductive health services to 
populations in need, especially key populations. During the 
COVID-19 pandemic, Fundación Huésped adapted rapidly 
to the COVID-19 context by expanding the use of telehealth 
and providing all staff with the necessary equipment for 
remote work. The only required physical visit to the clinic 
was for sample collection for testing. The expanded use 
of telephone and virtual consultations enabled Fundación 
Huésped to reach a greater number of people from a wider 
geographical area. Between March and November 2019, the 
15 staff members of Fundación Huésped provided services 
to 1500 clients per month versus 330 clients per month 
during the same period in the previous year.
Other community-based organizations in the Region adopted 
similar approaches. Community-based clinic Colectivo 
Amigos Contra el SIDA in Guatemala City, one of the largest 
HIV and STI community clinics in Central America for gay 
men and other men who have sex with men, introduced HIV 
self-testing to maintain sexual health services for gay men 
and other men who have sex with men. Clients could request 
test kits through the clinic’s website and receive them by 
mail. The clinic also adopted multimonth dispensing of 
PrEP and other essential supplies. As a result, not only were 
services maintained within the city but men outside the city 
could also access services with online support.
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4.3 South-East Asia Region
The South-East Asia Region has some of the 
world’s leading programmes for key populations 
and community-based responses. Three countries 
in the Region have been validated for EMTCT of 
HIV and syphilis and four countries have been 
certified to have achieved hepatitis B control 
through immunization. Progress in the response 
to HIV and STIs has nevertheless plateaued. 
Financing for HIV, viral hepatitis and STIs needs 
to be sustained and expanded towards universal 
health coverage.
Table 16. South-East Asia Region: data at a glance, 2019–2020
Disease area Indicator Numbers
HIV (2019) People acquiring HIV 160 000 
[110 000–210 000]




Incident cases of hepatitis B infection 260 000
[180 000–590 000]
Incident cases of hepatitis C infection 230 000
[200 000–430 000]
People dying from hepatitis B infection 180 000
[140 000–300 000]
People dying from hepatitis C infection 38 000
[37 000–130 000]
STIs (2020) Incident cases of gonorrhoea 21 100 000
[7 600 000–45 000 000]
Incident cases of syphilis 350 000
[110 000–600 000]
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Table 17. Regional highlights and priority actions
• Enhance the coverage of prevention and testing services 
with linkage to treatment.
• Reinvigorate programmes with increased focus on key 
populations and people at higher risk.
• Address barriers to accessing services, including stigma 
and discrimination.
• Give priority to hepatitis, HIV and STI within universal 
health coverage and with improved financing and 
investment cases.
• Advance a triple elimination framework to end mother-to-
child transmission of HIV, hepatitis B and syphilis.
• Utilize price advantages fully, since the costs of health 
commodities vary greatly in the Region.
• Strengthen surveillance and disease burden estimates 
with better collection and utilization of data.
• Maximize the potential of decentralized approaches, 
including the private sector, to achieve universal health 
coverage.
There are several best practices 
in STI control in the Region 
at subnational levels, even in 
countries with uneven overall 
implementation.
Trends in curable STIs are declining 
overall, except syphilis in a couple 
of instances. STI surveillance in the 
Region remains weak.
Eight countries in the Region have 
an official national STI strategy; 
among these, it is integrated with 
the national HIV strategy in five 
countries. However, there has been 
a relative lack of commitment and 
giving priority to STIs in the Region 
overall.
Screening for STIs among key 
populations and in antenatal care 
settings is low, with many missed 
opportunities.
The number of people acquiring HIV 
declined by 22% and the number 
of people dying from AIDS-related 
causes decreased by 26% between 
2015 and 2019. However, progress 
has plateaued, and members of key 
populations and their partners are 
acquiring HIV.
HIV treatment coverage increased 
from 39% in 2015 to 60% in 2019, but 
the region is off-track for achieving 
the 2020 targets.
The uptake of HIV self-testing and 
PrEP has been slow; and progress 
in addressing comorbidities such as 
HIV and TB has been insufficient.
In response to COVID-19, several 
countries applied differentiated 
and innovative approaches such 
as increased use of telemedicine 
and multimonth dispensing and 
take-home doses of HIV treatment 
and opioid substitution therapy and 
engaging communities as effective 
partners in service delivery.
Eight countries in the Region have 
national hepatitis strategic plans.
There have been strong gains in 
coverage of hepatitis B vaccination, 
and four countries in the Region 
have achieved 2020 control 
targets through immunization. The 
prevalence of hepatitis B infection 
has declined significantly.
There has been slow progress 
in scaling up access to hepatitis 
diagnosis and treatment, and 
mortality has not yet declined.
Funding for viral hepatitis remains 
inadequate, and the prices of 
commodities vary across countries.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
Three countries – Maldives, Sri Lanka and Thailand – have been validated as achieving elimination of mother-to-child 
transmission of HIV and syphilis. Access to harm reduction in the Region is low.
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Box 20.  
Community-led interventions for improving health outcomes  
across the Region
Several community-led initiatives are demonstrating 
their potential to improve health outcomes for affected 
populations and provide valuable lessons for wider scale-up 
within the Region and beyond. For example, a community-
based organization for female, male and transgender sex 
workers in southern India has demonstrated improvements 
in coverage, utilization and outcomes of HIV and STI 
services with a shift from implementation with sex workers 
as active partners towards programmes run by them (73). 
In a participatory training initiative in Thailand, people living 
with HIV and members of key populations were co-trainers 
alongside health facility staff (74). This initiative significantly 
reduced stigma and discrimination among health-care 
workers towards people living with HIV and key populations. 
Experiences from Indonesia among gay men and other 
men who have sex with men highlight the importance of 
social support from buddies in HIV treatment initiation and 
adherence (75).
Experiences across the Region have also demonstrated 
how interventions that place communities at the centre 
can achieve strong health outcomes (76). In Nepal, a 
community-based intervention leveraged existing sites 
providing opioid substitution therapy for people who inject 
drugs and provided hepatitis C virus screening and linkage 
to treatment. The role of communities has also been well 
recognized in other areas such as in advocacy for access 
to medicines for hepatitis C (77–79). During the COVID-19 
pandemic, community-based organizations played critical 
roles in providing immediate, short-term mitigation efforts 
(80). Nevertheless, these experiences also underscore the 
need for reconsidering social protection arrangements, 
addressing structural barriers and providing support 
to communities to ensure sustained ownership and 
involvement (81).
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4.4 European Region
Gaps in testing and treatment for HIV, viral 
hepatitis and STIs need to be filled rapidly in 
the European Region. There have been major 
advances in hepatitis programme planning, but 
the estimated number of people acquiring HIV 
has been increasing.
Table 18. European Region: data at a glance, 2019–2020
Disease area Indicator Numbers
HIV (2019) People acquiring HIV 190 000
[160 000–240 000]




Incident cases of hepatitis B infection 19 000
[9 400–38 000]
Incident cases of hepatitis C infection 300 000
[240 000–320 000]
People dying from hepatitis B infection 43 000
[34 000–51 000]
People dying from hepatitis C infection 64 000
[39 000–72 000]
STIs (2020) Incident cases of gonorrhoea 3 800 000
[1 500 000–7 300 000]
Incident cases of syphilis 240 000
[130 000–340 000]
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Table 19. European Region: highlights and priority actions
A total of 38 countries have policies 
and/or guidelines on STI diagnosis 
and treatment.
Non–European Union countries 
have limited data on STIs.
The number of people acquiring HIV 
has been increasing in the Region.
Service coverage is improving – 78% 
of people living with HIV know their 
HIV status, 74% of those who know 
their HIV-positive status receive 
antiretroviral therapy and 92% of 
those on treatment have suppressed 
viral loads; but the 2020 targets 
have not been reached.
The “treat all” policy has been 
implemented in all countries. The 
transition to dolutegravir has been 
slow due to the high cost in some 
middle-income countries.
The scale-up of PrEP has been slow.
A total of 33 countries in the Region 
have national hepatitis strategic 
plans.
The scale up of diagnostics and 
treatment has been slow.
There are major gaps in hepatitis 
data.
HIV Viral hepatitis Sexually transmitted infections
• Catch-up plan for COVID-19-related slowdown in progress 
on key interventions.
• Tailor prevention to key populations, with an integrated 
people-centred approach across disease areas.
• Take an integrated approach to addressing harm 
reduction and mental health for key populations.
• Use PrEP as an opportunity for better STI screening and 
treatment in key populations.
• Strengthen civil society involvement in the regional 
response.
• Decentralize and simplify HIV testing.
• Scale up early antiretroviral therapy provision with 
optimized regimens and improved quality of care.
• Strengthen hepatitis surveillance and monitoring 
and evaluation to better understand the situation and 
progress.
• Increase the number of countries with funded national 
plans for hepatitis.
• Simplify hepatitis testing strategies and treatment and 
improve access to treatment.
• Strengthen STI surveillance.
PRIORITY  
ACTIONS
• Harm reduction continues to be a low priority in some countries.
• The costs of medicines and diagnostics remain high in middle-income countries that face patent-related barriers.
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Box 21.  
Expanding access to hepatitis C treatment in Belarus through state 
funding and local production
An estimated 100 000 people live with chronic hepatitis C 
in Belarus. Most new cases occur among the working-age 
population, and liver cirrhosis caused by chronic hepatitis 
C is the most common indication for liver transplantation 
in Belarus.
Since 2018, the Government of Belarus has funded direct-
acting antiviral drugs for people with chronic hepatitis 
C infection across the country. Belarus also updated its 
national protocol for diagnosis, treatment and care for 
people with chronic hepatitis C and developed a 10-year 
plan for expanding access to hepatitis C treatment from 
2019 to 2028. In 2019, 6000 courses of the pangenotypic 
regimens of sofosbuvir and daclatasvir were procured 
through the state budget and distributed to health 
facilities. Among 6074 people treated in 2018–2019 with 
known treatment outcomes, 6062 (99.8%) had successful 
treatment outcomes.
With a strong commitment to ensure the sustainability of 
state-funded hepatitis-related activities, the Government of 
Belarus also established local production of generic direct-
acting antiviral drugs. As of 1 September 2018, the cost of a 
12-week treatment regimen was about US$ 706, lower than 
some other countries in the Region. The Ministry of Health 
continues to work to further reduce costs in cooperation 
with the pharmaceutical industry, representatives of 
patient organizations, infectious diseases specialists and 
international partners. In November 2018, Belarus hosted 
the Eastern Europe and Central Asia Second Regional 
Consultation on Expanding Access to Affordable and Quality 
Assured Medicines and Diagnostic Technologies to make 
continued use of the best global and regional practices and 
tools to ensure the quality, safety and efficacy of essential 




4.5 Eastern Mediterranean Region
The Eastern Mediterranean Region leads the 
way in scaling up access to hepatitis C testing 
and treatment, and some countries have an 
opportunity to move towards elimination. The 
impact of these population-based approaches 
needs to be expanded and transferred to 
hepatitis B, STI and HIV services.
Table 20. Eastern Mediterranean Region: data at a glance, 2019–2020
Disease area Indicator Numbers
HIV (2019) People acquiring HIV 44 000 
[33 000–67 000]




Incident cases of hepatitis B infection 100 000
[79 000–140 000]
Incident cases of hepatitis C infection 470 000
[240 000–520 000]
People dying from hepatitis B infection 33 000
[26 000–60 000]
People dying from hepatitis C infection 31 000
[31 000–74 000]
STIs (2020) Incident cases of gonorrhoea 5 300 000
[1 900 000–11 300 000]
Incident cases of syphilis 640 000
[240 000–1 000 000]
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Table 21. Eastern Mediterranean Region: highlights and priority actions
• Expand the use of people-centred and differentiated 
service delivery models and targeted interventions for 
prevention, diagnosis and treatment for key populations.
• Expand access to hepatitis diagnosis and treatment, 
including with a focus on microelimination in high-burden 
populations and continue to pursue price reduction 
strategies and public health approaches for scale-up.
• Renew the focus on STIs through greater integration with 
HIV and other health programme areas and efforts to 
mobilize resources.
• Promote domestic funding and mobilize catalytic cross-
cutting funding.
• Make joint efforts to strengthen strategic information 
for HIV, viral hepatitis and STIs as part of broader 
health management information system strengthening, 
including with support for electronic data collection and 
promoting data use through improved analytics and 
visualization dashboards.
There is a limited focus on STIs in 
the Region.
Some countries such as Egypt and 
Lebanon have conducted surveys 
on STIs among subpopulations, 
but overall data are lacking to 
accurately describe the burden 
of STIs in the Region, and STI 
surveillance systems are weak.
Access to HIV testing and treatment 
services is improving, yet coverage 
remains low. Only 37% of people 
living with HIV know their HIV 
status.
Some countries are expanding 
client-centred approaches such as 
HIV self-testing and PrEP, to expand 
outreach to key populations.
Linkages to care and retention are a 
challenge, and a search-and-rescue 
initiative is being implemented in 
countries such as Pakistan and 
Sudan to identify people living with 
HIV who may be lost to follow-up 
and relink them to care.
HIV services for refugees and other 
displaced people are expanding with 
support from international partners.
The availability and quality of data 
are improving with surveys and 
cascade analyses in countries such 
as Lebanon Morocco, Pakistan 
and Sudan; however, data systems 
remain fragmented and weak.
Strategic information systems for 
hepatitis data are slowly improving, 
and two countries have conducted 
serological surveys.
There has been strong momentum 
and progress with major initiatives in 
champion countries such as Egypt 
and Pakistan; however, programmes 
in most countries remain weak with 
limited funding.
Coverage of hepatitis B virus vaccine 
has increased to exceed 80% for the 
third dose, but birth dose coverage 
is low.
Diagnosis and treatment of hepatitis 
B and C infection is low.
Many countries have achieved 
reductions in the price of direct-
acting antiviral drugs for hepatitis C 
infection through price negotiations 
and local manufacturing.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
There has been progress in harm reduction, with favourable policies adopted in Egypt and Pakistan, but overall coverage of 
harm reduction among people who inject drugs in the Region remains very low.
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Box 22.  
Public health scale-up of 
hepatitis C diagnosis and 
treatment in Egypt
Egypt is one of the countries with the largest burden of 
hepatitis C infection in the world. It has made significant 
advances since 2018 towards eliminating hepatitis C, 
supported by strong government commitment, local 
generic manufacturing and price reductions obtained 
through negotiations with manufacturers. During 
2017–2018, Egypt conducted a massive countrywide 
effort to screen the entire population aged 18 years and 
older and provide treatment free of charge to everyone 
with infection. Nearly 60 million people had been tested 
by late 2019, and 4 million had started treatment. This 
constitutes one of the largest public health efforts to 
date towards eliminating hepatitis C in low- and middle-
income countries worldwide. Egypt now plans to support 
countries in the African Region in their scale-up efforts.
Box 23.  
Microelimination of viral 
hepatitis in a high-burden 
district in Pakistan
In the Punjab province in Pakistan, the Hepatitis Control 
Program implemented a demonstration microelimination 
project in the high-prevalence district of Nankana 
Sahib. Within this district, subarea Panwan with a 
total population of 29 500 people, concentrated in five 
villages, was selected for this initiative, with the aim of 
testing 95% of the population 12–80 years old. During 
a three-week pretest phase in 2019, health education 
sessions were conducted at the community level, 96% of 
the target population was screened for hepatitis B and 
C virus and people diagnosed were linked to treatment. 
The efforts were backed by strong political commitment 
and local ownership. The experience provides lessons 
for pursuing hepatitis microelimination efforts in other 
geographical areas of Pakistan and in other countries.
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4.6 Western Pacific Region
The Western Pacific Region has made major 
progress in expanding access to services for 
people with hepatitis B and C virus infection, 
largely from domestic funding and substantial 
reductions of drug prices. The responses to viral 
hepatitis, HIV and STIs have opportunities in 
national financing for universal health coverage.
Table 22. Western Pacific Region: data at a glance, 2019–2020
Disease area Indicator Numbers
HIV (2019) People acquiring HIV 110 000 
[71 000–150 000]




Incident cases of hepatitis B infection 140 000
[96 000–210 000]
Incident cases of hepatitis C infection 230 000
[220 000–260 000]
People dying from hepatitis B infection 470 000
[200 000–490 000]
People dying from hepatitis C infection 77 000
[77 000–140 000]
STIs (2020) Incident cases of gonorrhoea 23 200 000
[11 200 000–40 700 000]
Incident cases of syphilis 1 100 000
[620 000–1 600 000]
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Table 23. Western Pacific Region: highlights and priority actions
• Maximize opportunities for integrating services based 
on local epidemiology and context, including across 
reproductive health services, HIV, viral hepatitis and 
TB services and noncommunicable diseases, and 
decentralize integrated services to the primary health 
care level.
• Pursue high-level advocacy for domestic financing and 
multisectoral collaboration, including the private sector, 
and promote an integrated health financing approach.
• Promote the active involvement of communities for 
advocacy, stigma and discrimination reduction and 
service delivery.
• Integrate strategic information into existing systems and 
simplify data collection to improve quality and increase 
use.
Treatment guidelines have been 
revised in 21 countries to include 
WHO recommendations for 
dual treatment of people with 
gonorrhoea.
Disease burden estimates were 
modelled in five countries, but the 
overall availability and quality of 
STI data are weak.
Countries such as Cambodia and 
the Philippines are implementing 
initiatives to combat antimicrobial 
resistance.
Several innovative interventions 
have been introduced to expand 
service outreach, driven in part by 
the COVID-19 pandemic, including 
community-led interventions using 
online platforms to reach people 
with information and increase 
access to services.
New interventions, including PrEP, 
HIV self-test and lay-provider 
testing, have been introduced in 
seven countries.
The fixed-dose combination of 
tenofovir disoproxil fumarate + 
lamivudine + dolutegravir has been 
introduced in six priority countries.
Needle and syringe distribution 
targets have been met in Australia 
and Cambodia.
National action plans are in place in 
20 countries, strategic information 
action plans in seven countries and 
investment cases, including disease 
burden and economic analysis, have 
been developed in 13 countries.
The coverage of hepatitis services is 
expanding through domestic funding 
in 19 countries.
Drug prices have been reduced 
substantially, and hepatitis 
medicines have been included in 
national health insurance in China 
and Mongolia. Malaysia applied 
TRIPS flexibilities to expand access 
to hepatitis C medicines.
Hepatitis services are being scaled 
up at primary health care level in 10 
countries.
Public–private partnership service 
delivery models are being rolled out 
in Papua New Guinea.
HIV Viral hepatitis Sexually transmitted infections
PRIORITY  
ACTIONS
One country has achieved elimination of mother-to-child transmission of HIV and syphilis.
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Box 24.  
Unblocking the barrier of high drug prices to achieve universal coverage 
for hepatitis medicines in China
In 2015, access to treatment was limited for China’s 
estimated 96 million people living with hepatitis B and C 
virus. Tenofovir disoproxil fumarate to treat hepatitis B 
virus was under patent protection and cost US$ 2950 per 
year. The price of generic entecavir was US$ 1300–1400 
per year, and the originator price was US$ 1600–2000 per 
year. The price of hepatitis C medicines was US$ 10 000 for 
a cure. These medicines were not universally and equitably 
reimbursed through health insurance throughout the 
country, so most people were paying out of pocket.
To address this major barrier, WHO supported the 
government and stakeholders in performing economic 
analysis and health technology assessment of new 
medicines and facilitated round-table discussions on 
intellectual property rights and sharing of drug price 
information from other countries. The National Health 
Commission was able to use this information to successfully 
negotiate a price reduction for tenofovir disoproxil fumarate 
to US$ 960 per year in 2016, and the prices of entecavir were 
reduced accordingly. The government continued its pursuit 
of universal coverage in successive years by including 
hepatitis B and C medicines in the national reimbursement 
drug list and centrally pooled procurement. In early 2021, 
hepatitis C treatment cost US$ 1500–2000 for a cure, a 
reduction of 20%, and for hepatitis B virus costs US$ 10 
per year, a reduction by an astounding factor of 300. The 
reduction in prices enabled these medicines to be covered 
in the national health insurance, providing affordable care to 




Looking ahead to 2030
Eliminating HIV, viral hepatitis 
and STIs as public health threats 
will require collective efforts 
towards universal health coverage 
and global health security, 
leveraging the resilience and 
innovation seen in the global 
response to COVID-19.
The pandemic has exposed the deep social, economic and 
gender inequalities that make some people more vulnerable to 
disease and determine their health outcomes. The population 
groups most severely affected by HIV, viral hepatitis and 
STIs also encounter the greatest stigma, discrimination and 
marginalization and face difficulty in accessing the services they 
need. In some ways, they are tracer populations for the progress 
of inclusive and innovative universal health coverage that 
reaches beyond health facilities into communities.
The massive expansion in service delivery that will be required 
over the next decade must be matched by efforts to tackle 
the structural barriers that undermine the response. To get 
close to elimination, all countries must continue to go beyond 
heath service delivery to address the social and structural 
determinants of health and equitably serve the populations 
most severely affected and at higher risk. Communities must be 
fully resourced to play their role in reaching those who are hard 
to reach, delivering services, advocating for change and holding 
decision-makers accountable. People-centred health services 
means tailoring services to people but also involving them in a 
new partnership in their delivery.
Shifting towards elimination was always going to require a leap 
forward in our approaches. The lessons from the COVID-19 
response provide a historical opportunity to foster greater 
solidarity and innovation in the response to infectious diseases 
over the next decade. Disease-specific responses and the goals 
of primary health care, universal health coverage and health 
security are mutually reinforcing and need to be advanced 
through an integrated health systems approach. Closer links 
between HIV, viral hepatitis and STI services with related 
communicable and noncommunicable disease services can 
make intervention more efficient and improve their coverage 
and quality. Joint efforts to strengthen clinical and laboratory 
platforms, logistics management, information systems and 
human resource planning offer many opportunities to jointly 
strengthen health systems that will be resilient, adaptable and 
equitable, including to address future pandemics.
Achieving this requires learning from the fragility and solidarity 
of global health experienced with COVID-19 and ensuring 
renewed political commitment and sustainable financing to 
take the response to HIV, viral hepatitis and STIs to the next 
level. Such a response must be anchored in the principles of 
human rights and social justice. By acting decisively now, we 
can emerge stronger from the challenge of COVID-19 and use 
this momentum to reach the goals of the 2030 Agenda for 
Sustainable Development.
Despite major progress over the past decade, the 2020 targets 
were off-track in major areas even before the COVID-19 
pandemic. The ambition of the next decade to eliminate HIV, 
viral hepatitis and STIs as public health threats by 2030 is 
enormous yet feasible.
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5. Looking ahead to 2030
Box 25.  
Developing global health sector strategies for HIV, viral hepatitis  
and STIs for 2022–2030
As the global health sector strategies 2016–2021 reach 
the end of their implementation period, WHO will lead a 
consultative process to develop the next phase of the 
strategies to guide action towards eliminating these 
infections as public health threats by 2030. Taking into 
account the progress achieved to date and remaining gaps 
in achieving 2030 goals, the process will define the way 
forward for country and WHO action over the next decade.
Although many of the core public health interventions 
and target populations of the strategies remain relevant, 
there have been contextual shifts that must be considered 
in the next phase. The COVID-19 pandemic has strongly 
affected public health worldwide, drawing attention to the 
risks of unprepared health systems, exposing the social 
determinants of health and spurring innovations. The new 
strategies will ensure that the global response to HIV, viral 
hepatitis and STIs responds to these shifts to deliver health 
for all.
The new strategies will also take into account 
epidemiological and technological developments since 2016, 
such as updated estimates of the burden of disease, the 
availability of new diagnostics and medicines and advances 
in service delivery approaches. They will also consider 
the evolving global landscape of shifts in domestic and 
donor funding and align with political commitments such 
as those on primary health care (the 2018 Declaration of 
Astana (67)) and universal health coverage (United Nations 
General Assembly Resolution A/RES/74/2 (68)). They will 
promote synergy with other global strategy processes such 
as the UNAIDS post-2021 global AIDS strategy and the 
new strategy under development for the Global Fund. To 
strengthen accountability, the strategies will include interim 
targets for 2025 as milestones towards 2030 goals.
WHO’s technical leadership, normative guidance and country 
support remain critical for Member States and partners to 
implement the next phase. The new strategies will ensure 
that WHO remains well positioned to provide leadership 
on achieving the 2030 targets for HIV, viral hepatitis and 
STIs as part of the broader goals of primary health care and 
universal health coverage.
The strategy development process will include consultations 
with Member States, partners, civil society, communities 
and other stakeholders and public online consultations in 
the official WHO languages. These consultations will be held 
during 2021, with a view to presenting the final strategies for 
consideration by the World Health Assembly in May 2022. 
The current strategies will remain active until that time.
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